US20030143274A1 - Medical uses of in situ formed gels - Google Patents
Medical uses of in situ formed gels Download PDFInfo
- Publication number
- US20030143274A1 US20030143274A1 US10/234,922 US23492202A US2003143274A1 US 20030143274 A1 US20030143274 A1 US 20030143274A1 US 23492202 A US23492202 A US 23492202A US 2003143274 A1 US2003143274 A1 US 2003143274A1
- Authority
- US
- United States
- Prior art keywords
- drug delivery
- delivery composition
- group
- gel
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00802—Methods or devices for eye surgery using laser for photoablation
- A61F9/00817—Beam shaping with masks
- A61F9/00819—Beam shaping with masks with photoablatable masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00872—Cornea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/902—Method of implanting
- Y10S623/905—Eye
Definitions
- This invention relates to drug delivery system, the prevention of post-surgical adhesions, ophthalmic corneal protective devices, and a surgical device used in the correction, for instance, of corneal ulcers, irregularities, scarring, astigmatism, myopia, and hyperopia.
- Ionic polysaccharides have been used in the application of drugs by controlled release. Such ionic polysaccharides as chitosan or sodium alginate are disclosed as useful in providing spherical agglomerates of water-insoluble drugs in the Journal of Pharmaceutical Sciences volume 78, number 11, November 1989, Bodmeier et al. Alginates have also been used as a depot substance in active immunization, as disclosed in the Journal of Pathology and Bacteriology volume 77, (1959), C. R. Amies. Calcium alginate gel formulations have also found use as a matrix material for the controlled release of herbicides, as disclosed in the Journal of Controlled Release, 3 (1986) pages 229-233, Pfister et al.
- a molded plastic mass composed of the reaction product of a hydrophilic colloid and a cross-linking agent such as a liquid polyol, also containing an organic liquid medium such as glycerin, is disclosed as useful in the controlled release of medication or other additives.
- the hydrophilic colloid can be carboxymethyl cellulose gum or a natural alginate gum which is cross-linked with a polyol. The cross-linking reaction is accelerated in the presence of aluminum and calcium salts.
- compositions are disclosed for the controlled release of pharmacological macromolecular compounds contained in a matrix of chitosan.
- Chitosan can be cross-linked utilizing aldehydes, epichlorohydrin, benzoquinone, etc.
- osmotic drug delivery systems are disclosed in U.S. Pat. No. 4,439,196 which utilize a multi-chamber compartment for holding osmotic agents, adjuvants, enzymes, drugs, pro-drugs, pesticides, and the like. These materials are enclosed by semipermeable membranes so as to allow the fluids within the chambers to diffuse into the environment into which the osmotic drug delivery system is in contact.
- the drug delivery device can be sized for oral ingestion, implantation, rectal, vaginal, or ocular insertion for delivery of a drug or other beneficial substance. Since this drug delivery device relies on the permeability of the semipermeable membranes to control the rate of delivery of the drug, the drugs or other pharmaceutical preparations, by definition, are not isotonic with mammalian blood.
- Corneal protective devices are needed in cases in which corneal injury occurs and the immobilization of the eye using an eye patch is not resorted to. Molded collagen shields have been developed for this use. These are often not satisfactory because they lack sufficient flexibility to adequately conform to the individual corneal curvature. Wetting a collagen shield will increase conformance of the shield to the cornea but fragmentation can occur upon exceeding the flexibility of the collagen shield.
- the clinical uses of collagen shields are disclosed by Tru et al. in Journal of Cataract Refractive Survey , Volume 14, September 1988, pages 489-491. The author describes the use of collagen shields immersed in tobramycin solution in order to rehydrate the collagen prior to use. These are described as useful following cataract extraction or in patients having nonsurgical epithelial healing problems.
- Collagen shields have also been utilized as agents for the delivery of drugs to the cornea as disclosed in Reidy et al. Cornea , in press, 1989 the Raven Press, Ltd., New York and Shofner et al., Ophthalmology Clinics of North America , Vol. 2, No. 1, March 1989, pages 15-23.
- Laser keratectomy has been shown to be capable of yielding a more accurately controlled depth of corneal excision since each individual laser pulse excises a specific amount (0.2 to 10.0 um) of corneal tissue. Accordingly, the depth of excised tissue is in theory uniform and predictable, provided that the energy distribution is homogeneous across the laser beam. Since the primary locus of astigmatism is in the cornea, surgical intervention for astigmatism is more important than for the correction of other refractive errors, especially since spectacle or contact lens correction is of limited value in compensating for large astigmatic errors.
- Ionic polysaccharides have been used in the application of drugs by controlled release. Such ionic polysaccharides as chitosan or sodium alginate are disclosed as useful in providing spherical agglomerates of water-insoluble drugs in the Journal of Pharmaceutical Sciences, volume 78, number 11, November 1989, Bodmeier et al. Alginates have also been used as a depot substance in active immunization, as disclosed in the Journal of Pathology and Bacteriology, volume 77, (1959), C. R. Amies. Calcium alginate gel formulations have also found use as a matrix material for the controlled release of herbicides, as disclosed in the Journal of Controlled Release, 3 (1986) pages 229-233, Pfister et al. Alginates have also been used to form hydrogel foam wound dressings, as disclosed in U.S. Pat. No. 4,948,575.
- compositions and a process for drug or diagnostic agent delivery by topical, injection, or body cavity delivery are disclosed.
- the pharmaceutical compositions in one embodiment of the invention contain pharmacologically active medicaments which are useful in providing treatments to ophthalmic areas of the mammalian body requiring the controlled release application of a medicament or requiring the administration of a diagnostic agent.
- compositions of the invention are useful, with or without the inclusion of a medicament, as injectable compositions for depot drug delivery, as a protective corneal shield, as a second skin for application to wounds, as an ablatable corneal mask in a laser keratectomy process, or as medical devices, for instance, in the separation of organs, injured in surgical procedures or otherwise, in order to prevent the formation of undesirable adhesions as part of the healing process.
- compositions of the invention provide a physiologically acceptable vehicle having a buffered pH and hypoosmotic, hyperosmotic, or isoosmotic characteristics.
- the pH and osmotic pressure is, preferably, made similar to bodily fluids, such as lacrimal tears.
- the pH and osmotic pressure of lacrimal tears is about pH 7.4 and 290 m0sm/kg.
- the pharmaceutical compositions are, optionally, sterilized so as to insure that the pharmaceutical compositions of the invention do not provide a source of infection.
- Polyphase systems are also useful and may contain non-aqueous solutes, non-aqueous solvents, and other non-aqueous additives.
- Homogeneous, polyphase systems can contain such additives as water insoluble high molecular weight fatty acids and alcohols, fixed oils, volatile oils and waxes, mono-, di-, and triglycerides, and synthetic, water insoluble polymers without altering the functionality of the system.
- compositions of the invention in a preferred embodiment comprise aqueous mixtures of a film forming, water soluble polymer and an ionic polysaccharide, optionally containing a latent counter-ion to gel the polysaccharide upon release of the counter-ion.
- the compositions of the invention can comprise a two part aqueous system, one of which contains the ionic polysaccharide and film forming polymer and the other part containing an aqueous solution of a counter-ion.
- the counter-ion can be provided in latent form by microencapsulation in a heat sensitive medium, for instance, the walls of the microcapsule can be made of mono-, di-, or tri-glycerides or other natural or synthetic heat sensitive polymer medium.
- ion exchange resins can be incorporated in the compositions of the invention so as to release the desired counter-ion upon contact with an environment opposite in pH to the pH of the ion exchange resin.
- the aqueous mixture can be delivered to the ophthalmic area of the mammalian body requiring treatment as a low viscosity liquid at ambient temperatures. Activation of the latent form of the counter-ion gels the aqueous mixture in situ.
- the two part system can be separately applied to gel the mixture in situ. Because the compositions of the invention are low viscosity liquids at ambient temperatures, they easily pass to various ophthalmic areas insuring maximum contact between exposed tissue and the composition of the invention.
- the gel compositions of the invention can be either peeled away or allowed to be absorbed over time. The gels are gradually weakened upon exposure to mammalian body pH conditions.
- the useful film forming polymers are, preferably, water soluble polymers such as those which have been used in ophthalmic applications.
- the hydroxyalkyl cellulosics and methyl celluloses, sodium hyaluronate, and polyvinyl alcohol are representative polymers which have been found useful in ophthalmic applications.
- the useful ionic polysaccharides are natural polymers such as chitosan, gellan gum or alginates.
- Aqueous solutions of alginate ionic polysaccharides form gels upon contact with aqueous solutions of counter-ions such as calcium, strontium, aluminum, etc.
- Aqueous solutions of chitosan form gels upon contact with a metal tripolyphosphate counter-ion.
- the discovery forming the basis of this application is that when ionic polysaccharides are present in aqueous solutions in admixture with film forming polymers and a counter-ion, that such mixtures form useful gels.
- aqueous pharmaceutical vehicles containing a film forming polymer and an ionic polysaccharide can be gelled and rendered resistant to shear thinning by contacting the mixture with a counter-ion.
- the gel compositions can be made isotonic or iso-osmotic and adjusted to the pH of mammalian body fluids, such as lacrimal tears.
- the pH and osmotic pressure of such bodily fluids are 7.4 and 29U mOsm/kg, respectively.
- the, pharmaceutical compositions of the invention can be provided in a sterile condition.
- useful water soluble, film forming polymers are the water soluble alkyl celluloses, i.e., methyl and ethyl cellulose; the hydroxyalkyl celluloses, i.e., hydroxypropylemethyl cellulose and hydroxyethyl cellulose; hyaluronic acid and water soluble salts thereof, i.e., sodium hyaluronate; chondroitin sulfate and water soluble salts thereof i.e., sodium chondroitin sulfate; polymers of acrylamide, acrylic acid, and polycyanoacrylates; polymers of methyl methacrylate and 2-hydroxyethyl methacrylate; polydextrose, cyclodextrin; polydextrin; maltodextrin, dextran; polydextrose; gelatin, collagen, natural gums, i.e.
- xanthan locust bean, acacia, tragacanth, carrageenan, and agar
- derivatives of polygalacturonic acid such as pectin
- polyvinyl alcohol polyvinyl pyrrolidone
- polyethylene glycol polyethylene oxide
- a preferred film forming agent is carboxymethyl ullulose and its sodium salt.
- Cyclodextrin also known as cycloamylose is a cyclic oligosaccharide. Cyclodextrins are produced by the enzyme conversion of prehydrolized starch to a mixture of alpha, beta, and gamma cyclodextrins and some linear dextrins. The cyclodextrins are composed of glucose units linked together by alpha (1-4) glycosidic bonds.
- Sodium hyaluronate also known as hyaluronic acid is composed of repeating units of sodium glucuronate and N-acetylglucosamine.
- Sodium hyaluronate was originally extracted from the comb of the rooster.
- Hyaluronic acid is a common biological agent present in a number of sources including the human umbilical cord.
- Sodium hyaluronate can also be manufactured by fermentation of a strain of streptococcus zooepidemicus.
- Polydextrose is a randomly bonded condensation polymer of dextrose which is only partially metabolized by mammals.
- the polymer can contain a minor amount of bound sorbitol, citric acid, and glucose.
- Chondroitin sulfate also known as sodium chondroitin sulfate is a mucopolysaccharide found in every part of human tissue, specifically cartilage, bones, tendons, ligaments, and vascular walls. This polysaccharide has been extracted and purified from the cartilage of sharks.
- Carrageenan is a linear polysaccharide having repeating galactose units and 3,6 anhydrogalactose units, both of which can be sulfated or nonsulfated, joined by alternating 1-3 and beta 1-4 glycosidic linkages.
- Carrageenan is a hydrocolloid which is heat extracted from several species of red seaweed and irish moss.
- Maltodextrins are water soluble glucose polymers which are formed by the reaction of starch with an acid and/or enzymes in the presence of water.
- the gel forming ionic polysaccharides found useful in the represent invention are hydrophilic colloidal materials and include the natural gums such as gellan gum, alginate gums, i.e., the ammonium and alkali metal of salts of alginic acid and mixtures thereof.
- chitosan which is the common name for deacetylated chitin is useful.
- Chitin is a natural product comprising poly-(N-acetyl-D-glucosamine).
- Gellan gum is produced from the fermentation of pseudomonas elodea to yield an extracellular heteropolysaccharide.
- the alginates and chitosan are available as dry powders from Protan, Inc., Commack, N.Y. Gellan gum is available from the Kelco Division of Merck & co., Inc. San Diego, Calif.
- the alginates can be any of the water-soluble alginates including the alkali metal alginates, such as sodium, potassium, lithium, rubidium and cesium salts of alginic acid, as well as the ammonium salt, and the soluble alginates of an organic base such as mono-, di-, or tri-ethanolamine alginates, aniline alginates, and the like.
- the alkali metal alginates such as sodium, potassium, lithium, rubidium and cesium salts of alginic acid, as well as the ammonium salt
- the soluble alginates of an organic base such as mono-, di-, or tri-ethanolamine alginates, aniline alginates, and the like.
- about 0.2% to about 1% by weight and, preferably, about 0.5% to about 3.0% by weight of gellan, alginate or chitosan ionic polysaccharides, based upon the total weight of the composition are used to obtain the gel compositions of the invention.
- the drug delivery composition of the invention will contain about 0.01% to about 60% by weight of medicament or pharmaceutical, about 1% to about 50% by weight of the water soluble, film forming polymer, together with the above amounts of ionic polysaccharide and the balance of water.
- these amounts of gel forming ionic polysaccharide and water soluble, film forming polymer may be varied to increase or decrease the gel properties.
- carboxymethylcellulose may reduce the rate of erosion of the polymer when compared to the polymer without the carboxymethylcellulose.
- carboxymethylcellulose competes with the polymer for the association of the water molecule, therefore, enhancing the stability of the gel to remain intact when in an aqueous environment.
- Polysaccharides that have not been crosslinked, and can be used to enhance the physical properties of the gel include hydroxyalkyl cellulose and methylcellulose. More specifically, the useful polysaccharides are natural cellulose, hyaluronic acid and water soluble salts thereof, i.e. sodium hyaluronate, chondroitin sulfate and water soluble salts thereof, i.e. sodium chondroitin sulfate; polydextrose, cyclodextrin, polydextrin, maltodextrin, dextran; polydextrose; gelatin, collagen, natural gums, i.e. xanthan, locust bean, acacia, tragacanth, carrageenan, and agar, and derivatives of polygalacturonic acid such as pectin.
- a preferred polysaccharide is carboxymethylcellulose.
- the drug delivery composition of the invention will contain about a 0.1% to about 25% by weight of the non-crosslinked polysaccharide to enhance the physical properties of the gel.
- cross-linking is the physical, co-valent or ionic bonding of two or more molecules of the same polymer.
- Any cross linking agent having more than one functional group wherein the function group is either chemical or ionic may be utilized to cross link the polysaccharides described above.
- cross linking can occur between molecules of similar polymers by physical reaction as long as appropriate functional groups are present on the polymers.
- Useful counter-ions for gelling the gellan gum or alginate ionic polysaccharides in combination with the film forming, water soluble polymer compositions of the invention are cationic gelling agents, preferably, comprising a divalent or trivalent cation.
- Useful divalent cations include the alkaline earth metals, preferably, selected from the group consisting of calcium and strontium.
- Useful trivalent cations include aluminum.
- the most preferred counter-ions for gelling gellan gum or alginate ionic polysaccharides are contained in ionic compounds selected from pharmaceutically-acceptable gluconates, flourides, citrates, phosphates, tartrates, sulfates, acetates, borates, chlorides, and the like having alkaline earth metal cations such as calcium and strontium.
- ionic compounds selected from pharmaceutically-acceptable gluconates, flourides, citrates, phosphates, tartrates, sulfates, acetates, borates, chlorides, and the like having alkaline earth metal cations such as calcium and strontium.
- Especially preferred counter-ion containing inorganic salts for use as ionic polysaccharide gelling agents include such inorganic salts as the chloride salts, such as strontium chloride, calcium chloride, and mixtures thereof.
- the counter-ion such as calcium or other counter-ions may be obtained by contact of the compositions of the invention with bodily fluids
- a counter-ion in latent form be used in combination with the gellan gum or alginate ionic polysaccharide and film forming, water soluble polymer compositions of the invention.
- a counter-ion can be combined with the ionic polysaccharide and water soluble, film forming polymer compositions of the invention utilizing a two part system in which the counter-ion is topically or otherwise applied to the compositions of the invention subsequent to their topical or other application.
- incorporation of the counter-ion in a latent form together with the ionic polysaccharide and film forming, water soluble polymer compositions of the invention may be accomplished by either encapsulating an aqueous solution of one of the counter-ion gelling agents, previously described above or by the incorporation of the counter-ion gelling agent into a matrix which provides for the controlled, slow-release of gelatin-encapsulated controlled release compositions disclosed in U.S. Pat. No. 4,795,642, incorporated herein by reference, disclose the preparation of a gelatin shell encapsulating a controlled release formulation in which the gelatin composition includes calcium chloride as the gelling agent.
- the counter-ion can be incorporated as an aqueous solution of a cationic gelling agent encapsulated in a vesical composed, for instance, of alphatocopherol, as disclosed in U.S. Pat. No. 4,861,580, incorporated herein by reference.
- aqueous compositions comprising chitosan can be gelled with multivalent anion gelling agents, preferably, comprising a metal polyphosphate, such as an alkali metal or ammonium polyphosphates, pyrophosphates, or metaphosphates.
- a metal polyphosphate such as an alkali metal or ammonium polyphosphates, pyrophosphates, or metaphosphates.
- metaphosphate, pyrophosphate, and polyphosphate gelling agents include sodium and potassium, polyphosphates, sodium and potassium pyrophosphates, sodium and potassium metaphosphates, and sodium and ammonium (mono-, di-, tri-) phosphates.
- compositions of the invention as ophthalmic drug delivery compositions, laser ablatable shields, or corneal protective compositions
- the pH and osmolality of the pharmaceutical vehicle be matched to the pH and osmolality of the eye.
- a large percentage of drugs administered to the eye are lost as a result of lacrimal drainage. This applies especially in situations in which a liquid composition containing a pharmacologically active medicament is applied to the cornea of the eye.
- the liquid-gel phase transition compositions for ophthalmological use contain polymers which form gels at concentrations 10-100 fold lower than those used in systems such as the '751 Patent, involving thermogelation. Accordingly, the drug delivery vehicles for the '760 Patent are said to be very well tolerated by the eye.
- the polymers utilized in the drug delivery vehicles of the '760 patent are described as polysaccharides obtained by fermentation of a microorganism.
- the drug delivery vehicles and corneal protective shield compositions of the invention are an improvement over those compositions used in prior art methods of ophthalmological drug delivery in that the compositions can be not only optimized for physiological tolerance in the eye by formulating the vehicles useful as drug delivery compositions so as to have isoosmotic, hyperosmotic, and hypoosmotic characteristics in the gel state but are made more useful because of increased resistance to shear thinning, as the result of higher gel strength.
- drug delivery compositions of the invention By matching the osmolality of the drug delivery compositions of the invention, for instance, to those of the lacrimal fluid of the eye, it is possible to eliminate burning or other discomfort upon application of the drug delivery vehicles of the invention to the eye.
- the gel compositions formed upon contact with a counter ion for the ionic polysaccharide allow retention of the gel at the desired locus for longer intervals thus increasing the efficiency of action of the delivered drug.
- Drugs or diagnostic agents which can be administered by means of the drug delivery vehicles according to the invention are, for example:
- Antibacterial substances such as beta-lactam antibiotics, such as cefoxitin, n-formamidoylthienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides;
- beta-lactam antibiotics such as cefoxitin, n-formamidoylthienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides;
- aminoglycoside antibiotics such as gentamycin, kanamycin, amikacin, sisomicin and tobramycin;
- nalidixic acid and its analogs such as norfloxacin and the antimicrobial combination fluoroalanine/pentizidone, nitrofurazones and analogs thereof;
- antihistaminics and decongestants such as pyrilamine, chlorpheniramine, tetrahydrazoline, antazoline and analogs thereof; mast-cell inhibitors of histamine release, such as cromolyn;
- anti-inflammatories such as cortisone, hydrocortisone, hydrocortisone acetate, betamethasone, dexamethasone, dexamethasone sodium phosphate, prednisone, methylprednisolone, medrysone, fluorometholone, prednisolone, prednisolone sodium phosphate, triamcinolone, indainethacin, sulindac, its salts and its corresponding sulfides, and analogs thereof;
- miotics and anticholinergics such as echothiophate, pilocarpine, physostigmine salicylate, diisopropylfluorophosphate, epinephrine, dipivaloylepinephrine, neostigmine echothiopate iodine, demecarim bromide, carbamoyl choline chloride, methacholine, bethanechol, and analogs thereof;
- mydriatics such as atrophine, homatropine, scopolamine, hydroxyamphetamine, ephedrine, cocaine, tropicamide, phenylephrine, cyclopentolate, oxyphenonium, eucatropine, and analogs thereof;
- antiglaucama drugs for example, timalol, and especially its maleic salt and R-timolol and a combination of timolol or R-timolol with pilocarpine, as well as many other adrenergic agonists and/or antagonists: epinephrine and an epinephrine complex, or prodrugs such as bitartrate, borate, hydrochloride and dipivefrine derivatives; carbonic anhydrase inhibitors such as acetazolamide, dichlorphenamide, 2-(p-hydroxyphenyl)-thiothiophenesulfonamide, 6-hydroxy-2-benzothiazolesulfonamide; and 6-pivaloyloxy-2-benzothiazolesulfonamide;
- anitparasitic compounds and/or anti-protozoal compounds such as ivermectin, pyrimethamine, trisulfapidimidine, clindamycin and corticosteroid preparations;
- compounds having antiviral activity such as acyclovir, 5-iodo-2′-deoxyuridine (IDU), adenosine arabinoside (Ara-A), trifluorothymidine, interferon, and interferon-inducing agents such as poly I:C;
- antifungal agents such as amphotericin B, nystatin, flucytosine, natamycin and miconazole;
- anesthetic agents such as etidocaine cocaine, benoxinate, dibucaine hydrochloride, dyclonine hydrochloride, naepaine, phenacaine hydrochloride, piperocaine, proparacaine hydrochloride, tetracaine hydrochloride, hexylcaine, bupivacaine, lidocaine, mepivacaine and prilocaine;
- ophthalmic diagnostic agents such as:
- opthalmic agents used as adjuncts in surgery such as alpha-chymotrypsin and hyaluronidase;
- chelating agents such as ethylenediaminetetraacetic acid (EDTA) and deferoxamine;
- immunosuppressants and anti-metabolites such as methotrexate, cyclophosphamide, 6-mercaptopurine and azathioprine and combinations of the compounds mentioned above, such as antibiotics/antiinflammatories combinations such as the combination of neomycin sulfate and dexamethasone sodium phosphate and combinations concomitantly used for treating glaucoma, for example, a combination of timolol maleate and aceclidine.
- the drug delivery composition of the present invention will contain from about 0.01% to about 60% by weight of the medicament or pharmaceutical, from about 1% to about 50% of the polymer, the above amounts of ionic polysaccharide, and the balance water. In special situations, however, the amounts may be varied to increase or decrease the dosage schedule.
- the ophthalmic drug delivery vehicle, laser ablatable corneal mask, and corneal protective compositions of the invention may also contain preservatives, cosolvents, suspending agents, viscosity enhancing agents, ionic-strength and osmolality adjustors and other excipients in addition to the medicament and buffering agents.
- Suitable water soluble preservatives which may be employed in the inventive drug delivery vehicle are sodium bisulfite, sodium thiosulfate, is ascorbate, benzalkonilirn chloride, chlorabutanol, thimerosal, phenylmercurioborate, parabens, enzylalcohol phenylethanol and others. These agents may be present, generally, in amounts of about 0.001% to about 5% by weight and, preferably, in the amount of about 0.01 to about 2% by weight.
- Suitable water soluble buffering agents are alkali or alkali earth carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate, carbonate and tromethamine (TRIS). These agents are present in amounts sufficient to maintain the pH of the system at 7.4 ⁇ 0.2 and preferably, 7.4. As such the buffering agent can be as much as 5% on a weight basis of the total composition.
- Representative buffering agents or salts useful in maintaining the pH at about 7.4 ⁇ 0.2 are alkali or alkali earth carbonates, chlorides, sulfates, phosphates, bicarbonates, citrates, borates, acetates and succinates.
- Representative preservatives are sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzylalcohol and phenylethanol.
- the corneal mask compositions of the invention are an improvement over the prior art thermo-reversible gels containing a polyoxyalkylene polymer as the sole polymer, in that the compositions of the invention provide greater gel strength because they are more resistant to shear thinning and are characterized as thermally-irreversible.
- These advantages are obtained by the incorporation of an ionic polysaccharide in admixture with a water soluble, film forming polymer. They can be optimized for optimum physiological tolerance in the eye by formulating the compositions so as to have a neutral pH and isotonic characteristics. These former advantages are obtained by the incorporation of an ionic polysaccharide in a mixture with a water soluble, film forming polymer.
- the laser ablatable corneal mask compositions of the invention By matching the osmolality and pH of the laser ablatable corneal mask compositions of the invention to those of the lacrimal fluid of the eye, it is possible to eliminate burning or other discomfort upon application of the corneal mask of the invention to the eye.
- the higher gel strength compositions upon contact with a counter-ion allow retention of the gel as an in situ formed corneal mask for long intervals.
- composition of the invention suitable for ophthalmic use as a laser ablatable corneal mask or protective corneal shield.
- This composition was characterized as iso-osmotic and neutral in pH.
- An aqueous solution was made by dissolving the hydroxypropyl methyl cellulose in aqueous buffer solution together with the sodium alginate.
- the hydroxypropyl methyl cellulose was characterized as grade F50LV Premium, obtained from The Dow Chemical Company.
- the sodium alginate, characterized as high viscosity grade HF 120 was obtained from Protan, Inc.
- the proportions of ingredients in percent by weight are as follows: Hydroxypropyl methyl cellulose 2.0 Sodium Alginate, high viscosity 1.0 Glycerin 0.25 Boric acid-sodium borate buffer 96.75
- the boric acid-sodium borate buffer was prepared as follows: In a two liter volumetric flask, 24.7 grams of boric acid and 3.8 grams of sodium borate decahydrate were dissolved in two liters of purified water, Usp.
- the formulation of this Example had a measured pH of 7.2 and an osmolality of 277 MOSM/Kg. A small amount of the formulation was placed on a glass slide and evenly spread so as to create a thin film. The film was subsequently sprayed with an aqueous solution of calcium chloride having a concentration of 21 to about 5% by weight.
- the film was characterized as strong, transparent, and resembled a thin, soft hydrophilic corneal contact lens which would be useful as a protective corneal mask or as an ablatable mask useful in laser keratectomy.
- the product was further characterized by measuring the average penetration in millimeters determined using a Precision Penetrometer with a 1 ⁇ 4 size (9.38 grams, ASTM D-1043) cone and plunger.
- the penetration of the aqueous solution of polymers prepared above was greater than 20 mm.
- compositions of the invention for ophthalmic use as a corneal protective mask or as a laser ablatable corneal mask.
- an aqueous composition containing sodium hyaluronate and sodium alginate was prepared in two separate compositions.
- Sodium hyaluronate is commercially available from Meiji Seika Inc.
- Example 2 was hypoosmotic having an osmotic pressure of 249 mOSM/Kg and
- Example 3 was hyperosmotic having an osmotic pressure of 319 mosm/Kg. Both compositions were characterized as neutral in pH.
- Example 2 Sodium hyaluronate 1.0 1.0 Sodium Alginate, high viscosity 1.0 1.0 Glycerin 96.0 0.5 Boric acid-sodium borate buffer 98.0 97.5
- compositions were evaluated as described in Example 1 by spreading a small amount of the formulation a glass slide and subsequently spraying the coated slide with a 5% by weight aqueous solution of calcium chloride. Similar strong, transparent, soft films were obtained which would be useful as a protective corneal shield or as a laser ablatable corneal mask.
- Example 3 was further characterized by measuring the average penetration in millimeters determined using a Precision Penetrometer with a 1 ⁇ 4 size (9-38 grams, ASTM D-1043) cone and plunger. The penetration of the aqueous solution of polymers prepared above was greater than 20 mm. Subsequent to treatment of this solution with a few drops of a 2%-5% by weight aqueous solution of calcium chloride, a gel was formed in which the penetration was reduced to 5.9 mm.
- composition of the invention for ophthalmic use as a protective corneal shield or a laser ablatable corneal mask.
- An aqueous mixture comprising polyvinyl pyrrolidone and sodium alginate, high viscosity was prepared as follows: The percentages below are by weight. Polyvinyl pyrrolidone 0.8 Sodium Alginate, high viscosity 1.0 Glycerin 0.3 Boric acid-sodium borate buffer 97.9
- the composition was characterized as neutral in pH having a pH of 7.2.
- the composition was hypoosmotic having an osmolality of 270 mOsm/Kg.
- the product was further characterized by measuring the average penetration in millimeters determined using a Precision Penetrometer with a 1 ⁇ 4 (9.38, ASTM D-1043) cone and plunger.
- the penetration of the aqueous solution of polymers prepared above was greater than 20 mm.
- Example 1 In this Example there is described a composition of the invention for ophthalmic use as a laser ablatable mask or as a protective corneal shield.
- chondroitin sulfate and sodium alginate were prepared as an aqueous solution utilizing the percentages by weight indicated below.
- the aqueous solution was characterized as neutral in pH having a pH of 7.0.
- the aqueous solution was hyperosmotic having a measured osmolality of 354 mOsm/Kg.
- the penetration utilizing a Precision Penetrometer with a 1 ⁇ 4 size cone, as described above, was greater than 20 mm prior to treatment with a few drops of a 2%-5% aqueous solution of calcium chloride. Subsequent to treatment with the aqueous calcium chloride solution, a gel was formed in which the penetration was reduced to 5.1 mm.
- Ion exchange resin beads sold under the trade name Duolite were treated so as to incorporate calcium by first treating a 30 gram sample of the ion exchange resin with a solution of 0.1 molar hydrochloric acid so as to allow for the exchange of protons for sodium. After three washings with 0.1 molar hydrochloric acid, the beads were washed with water and then washed twice with a 2% aqueous solution of calcium chloride. Each of the washing steps took place over a period of 16 hours (overnight). The beads were thereafter filtered and washed with water utilizing coarse filter paper and a Buchner glass filter assembly. The beads were then left overnight in a desiccator to dry.
- the dried beads of ion exchange resin which were obtained are utilized in the amount of 2 grams to fill a first compartment (close to the needle of the syringe) of a glass syringe utilized to apply liquids and dry materials.
- the syringe is sold under the trademark Hypak.
- Into the second compartment of the syringe there is placed successively the solutions of Examples 1-5. Pushing the plunger of the syringe forward results in mixing the solution of Examples 1-5 with the ion exchange beads. After 5 to 10 minutes subsequent to mixing, the mixture is expelled from the syringe. After an additional 15 minutes the expelled material forms (without drying) a strong, transparent gel on the substrate on which it is expelled.
- the time required for the formation of a gel is less than 5 minutes. Thereafter, the contact lens is removed to expose a perfectly smooth and optically clear gelled surface of the composition of Examples 1 and 3-5.
- Excimer laser keratectomy is thereafter performed utilizing an argon fluoride excimer laser (193 mm). Further details of the excimer laser keratectomey process can be found in Archives of Ophthalmology , Vol. 106, Feb., 1988, entitled “Excimer Laser Keratectomy with a Rotating-slit Delivery System,” Hanna et al, incorporated herein by reference.
- EXAMPLE 16 CONTROL—Forming no part of this invention Percentage by weight Timolol maleate 0.50 Poloxamer 407 16.00 Sodium phosphate, monobasic, monohydrate 0.15 Sodium phosphate, dibasic 0.63 Glycerin 0.75 Sterile water 81.97
- An eye drop or medicated contact lens composition was prepared using a suitable glass container in which the sodium phosphate salts and glycerin were dissolved in sterile water.
- the polymer was next mixed with the buffer solution at 65° C. for 1 hour, followed by a further 2-3 hours in cold conditions.
- To a fixed weight of the polymer solution was added and dissolved, an accurate amount to timolol maleate (Huhtamaki OY Pharmaceuticals, Turku, Finland) to make a 0.5% w/w concentration.
- EXAMPLE 17 CONTROL—Forming no part of this invention Percentage by weight Timolol maleate 0.50 Poloxamer 17.00 Sodium alginate, high viscosity 1.50 Sodium borate, decahydrate 0.16 Glycerin 1.00 Sterile water 81.27
- a medicated contact lens was prepared using a suitable glass container in which the sodium borate, boric acid and glycerin were dissolved in sterile water. Sodium alginate was sprinkled in with stirring to form a uniform paste. The polymer was next mixed with this mixture at 65° C. for 1 hour, and for a further 2-3 hours under cold conditions. To a fixed weight of the polymer-alginate solution, was added and dissolved, and accurate amount of timolol maleate (Huhtamaki OY Pharmaceuticals, Turku, Finland) to make a 0.5% w/w concentration.
- a medicated contact lens was prepared using a suitable glass container in which the sodium borate, boric acid and glycerin were dissolved to make a solution in sterile water. Sodium alginate and sodium hyaluronate were sprinkled into this solution with continuous stirring to form a uniform paste. To a fixed weight of the hyaluronate-alginate mixture, there was added and dissolved an amount of timolol maleate (Huhtamaki OY Pharmaceuticals, Turku, Finland) to make a 0.5% w/w concentration.
- timolol maleate Huhtamaki OY Pharmaceuticals, Turku, Finland
- compositions having multiple uses. For instance, they may be used as vehicles for drug delivery by topical application or by injection or useful as a protective corneal shield or in a process for excimer laser keratectomy as a laser ablatable corneal mask.
- TRIS-hydrochloride buffer utilized in this composition was prepared utilizing the ingredients and proportions by weight indicated below.
- TRIS trcanethamine, USP
- Concentrated hydrochloric acid 0.4123 Purified water, USP 100
- composition was found to have a pH of 7.4 and an osmolality in mOsm/kg of 83.
- the procedure for preparation of this buffer is as follows: The weighed amount of TRIS was placed in a 2-liter volumetric flask and about 1 liter of purified water was added to the flask. The concentrated hydrochloric acid was added and the solution was made up to volume by adding the remaining water in the formulation.
- the calcium based counter-ion solution utilized to gel the inventive drug delivery compositions of Examples 19-22 was prepared utilizing the following proportion of ingredients in proportions by weight. Calcium chloride, dehydrate 1.2 Calcium gluconate, anhydrous 3.0
- the composition had a pH of 6.88 and an osmolality in mOsm/kg of 299.
- the calcium based counter-ion solution was prepared as follows: The Calcium gluconate and calcium chloride in the required amount were placed in a 200 ml volumetric flask. Approximately 100 ml of water were added to partially dissolve the salts. The solution was, thereafter, warmed to 80° C. to facilitate dissolution. The solution was cooled and the remaining water was added to make up to 200 ml volume.
- a composition containing both sodium alginate and sodium hyaluronate was prepared for use as a vehicle for drug delivery, a laser ablatable corneal mask, a protective corneal shield, or a composition for use in preventing post-surgical adhesions.
- the proportions by weight are as follows: Sodium hyaluronate 0.5 Sodium alginate 1.0 Sodium chloride 0.54 TRIS-hydrochloride Buffer 97.96
- composition was found to have a pH of 7.6 and an osmolality of 297 mosm/kg prior to treatment with calcium ions by the addition of the previously described calcium based counter-ion solution. After treatment with calcium ions the osmolality was 302 mosm/kg.
- the product was further characterized by measuring the average penetration in millimeters as determined using a precision penetrometer with a 1 ⁇ 4 size (9.38 grams, ASTM D-1043) cone and plunger.
- the penetration in millimeters prior to treatment of the composition of Example 19 with calcium ions was greater than 20 mm. After treatment with calcium ions the penetration was 4.77 mm.
- composition containing polyvinyl pyrrolidone and sodium alginate was prepared which is useful for the same applications as that formulation described in Example 19.
- the proportions in percent by weight of the ingredients of the composition are as follows: Polyvinyl pyrrolidone 0.8 Sodium alginate 1.0 Sodium chloride 0.62 TRIS-hydrochloride buffer 97.58
- composition had a pH of 7.59 and as osmolality in mOsm/kg prior to treatment with calcium ions of 320 and after treatment with calcium ions of 289.
- Example 19 The penetration utilizing a precision penetrometer as further described in Example 19 was greater than 20 prior to treatment of the composition with calcium ions and 6.57 after treatment with calcium ions.
- Example 19 A composition useful for the same uses as stated in Example 19 containing a combination of sodium alginate and chondroitin sulfate was prepared.
- the composition had a pH of 7.9 and an osmolality expressed in mOsm/kg of 301 prior to treatment with calcium ions and 272 after treatment with calcium ions.
- Example 19 A composition useful for the same uses as stated in Example 19 containing a combination of hydroxypropyl methyl cellulose, and sodium alginate was prepared.
- the proportions of ingredients and their percent by weight are as follows: Hydroxypropyl methyl cellulose 2.0 Sodium alginate 1.0 Sodium chloride 0.6 TRIS-hydrochloride buffer 96.7
- the composition had a pH of 7.59 and an osmolality expressed in mOsm/kg of 326 prior to treatment with calcium ions and 301 after treatment with calcium ions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.
Description
- This application is a continuation of U.S. Ser. No. 09/628,227, filed Jul. 28, 2000, which is a continuation of U.S. Ser. No. 09/330,618, filed Jun. 11, 1999, now U.S. Pat. No. 6,136,334, which is a continuation of U.S. Ser. No.08/773,755, filed Dec. 23, 1996, now U.S. Pat. No. 5,958,443 which is a continuation of U.S. Ser. No. 08/174,101 filed Dec. 28, 1993, now U.S. Pat. No. 5,587,175, which is a divisional of U.S. Ser. No. 07/785,305, filed Oct. 30, 1991, now U.S. Pat. No. 5,318,780.
- This invention relates to drug delivery system, the prevention of post-surgical adhesions, ophthalmic corneal protective devices, and a surgical device used in the correction, for instance, of corneal ulcers, irregularities, scarring, astigmatism, myopia, and hyperopia.
- Over the years, methods have been developed to achieve the efficient delivery of a therapeutic drug to a mammalian body part requiring pharmaceutical treatment. Use of an aqueous liquid which can be applied at room temperature as a liquid but which forms a semisolid gel when warmed to body temperature has been utilized as a vehicle for drug delivery since such a system combines ease of application with greater retention at the site requiring treatment than would be the case if the aqueous composition were not converted to a gel as it is warmed to mammalian body temperature. In U.S. Pat. No. 4,188,373, PLURONIC® polyols are used in aqueous compositions to provide thermally gelling aqueous systems. Adjusting the concentration of the polymer provides the desired sol-gel transition temperature, that is, the lower the concentration of polymer, the higher the sol-gel transition temperature, after crossing a critical concentration minimum, below which a gel will not form.
- In U.S. Pat. Nos. 4,474,751; '752; '753; and 4,478,822, drug delivery systems are described which utilize thermosetting gels; the unique feature of these systems is that both the gel transition temperature and/or the rigidity of the gel can be modified by adjustment of the pH and/or the ionic strength, as well as by the concentration of the polymer.
- Other patents disclosing pharmaceutical compositions which rely upon an aqueous gel composition as a vehicle for the application of the drug are U.S. Pat. Nos. 4,883,660, 4,767,619, 4,511,563, and 4,861,760. Thermosetting gel systems are also disclosed for application to injured mammalian tissues of the thoracic or peritoneal cavities in U.S. Pat. No. 4,911,926.
- Ionic polysaccharides have been used in the application of drugs by controlled release. Such ionic polysaccharides as chitosan or sodium alginate are disclosed as useful in providing spherical agglomerates of water-insoluble drugs in theJournal of Pharmaceutical Sciences volume 78, number 11, November 1989, Bodmeier et al. Alginates have also been used as a depot substance in active immunization, as disclosed in the Journal of Pathology and Bacteriology volume 77, (1959), C. R. Amies. Calcium alginate gel formulations have also found use as a matrix material for the controlled release of herbicides, as disclosed in the Journal of Controlled Release, 3 (1986) pages 229-233, Pfister et al.
- In U.S. Pat. No. 3,640,741, a molded plastic mass composed of the reaction product of a hydrophilic colloid and a cross-linking agent such as a liquid polyol, also containing an organic liquid medium such as glycerin, is disclosed as useful in the controlled release of medication or other additives. The hydrophilic colloid can be carboxymethyl cellulose gum or a natural alginate gum which is cross-linked with a polyol. The cross-linking reaction is accelerated in the presence of aluminum and calcium salts.
- In U.S. Pat. No. 4,895,724, compositions are disclosed for the controlled release of pharmacological macromolecular compounds contained in a matrix of chitosan. Chitosan can be cross-linked utilizing aldehydes, epichlorohydrin, benzoquinone, etc.
- In U.S. Pat. No. 4,795,642, there are disclosed gelatin-encapsulated, controlled-release compositions for release of pharmaceutical compositions, wherein the gelatin encloses a solid matrix formed by the cation-assisted gelation of a liquid filling composition incorporating a vegetable gum together with a pharmaceutically-active compound. The vegetable gums are disclosed as polysaccharide gums such as alginates which can be gelled utilizing a cationic gelling agent such as an alkaline earth metal cation.
- While the prior art is silent with respect to aqueous drug delivery vehicles and isotonicity thereof, osmotic drug delivery systems are disclosed in U.S. Pat. No. 4,439,196 which utilize a multi-chamber compartment for holding osmotic agents, adjuvants, enzymes, drugs, pro-drugs, pesticides, and the like. These materials are enclosed by semipermeable membranes so as to allow the fluids within the chambers to diffuse into the environment into which the osmotic drug delivery system is in contact. The drug delivery device can be sized for oral ingestion, implantation, rectal, vaginal, or ocular insertion for delivery of a drug or other beneficial substance. Since this drug delivery device relies on the permeability of the semipermeable membranes to control the rate of delivery of the drug, the drugs or other pharmaceutical preparations, by definition, are not isotonic with mammalian blood.
- Corneal protective devices are needed in cases in which corneal injury occurs and the immobilization of the eye using an eye patch is not resorted to. Molded collagen shields have been developed for this use. These are often not satisfactory because they lack sufficient flexibility to adequately conform to the individual corneal curvature. Wetting a collagen shield will increase conformance of the shield to the cornea but fragmentation can occur upon exceeding the flexibility of the collagen shield. The clinical uses of collagen shields are disclosed by Poland et al. inJournal of Cataract Refractive Survey, Volume 14, September 1988, pages 489-491. The author describes the use of collagen shields immersed in tobramycin solution in order to rehydrate the collagen prior to use. These are described as useful following cataract extraction or in patients having nonsurgical epithelial healing problems. More rapid healing of epithelial defects after surgery resulted from the use of the collagen shield. Collagen shields have also been utilized as agents for the delivery of drugs to the cornea as disclosed in Reidy et al. Cornea, in press, 1989 the Raven Press, Ltd., New York and Shofner et al., Ophthalmology Clinics of North America, Vol. 2, No. 1, March 1989, pages 15-23.
- Refractive surgery has been promoted in the United States and Russia over the past few years but its acceptance has been limited because of the poor predictability of the final optical results which include resulting glare from incisions that encroach upon the optical zone. Techniques that rely upon the surgical production of corneal incisions have yielded inconsistent results because these surgical incisions in the cornea have been found to vary considerably in depth and length.
- Laser keratectomy has been shown to be capable of yielding a more accurately controlled depth of corneal excision since each individual laser pulse excises a specific amount (0.2 to 10.0 um) of corneal tissue. Accordingly, the depth of excised tissue is in theory uniform and predictable, provided that the energy distribution is homogeneous across the laser beam. Since the primary locus of astigmatism is in the cornea, surgical intervention for astigmatism is more important than for the correction of other refractive errors, especially since spectacle or contact lens correction is of limited value in compensating for large astigmatic errors.
- The excimer laser was introduced to ophthalmology in 1983 (Trokel, S., et al., “Excimer surgery of the cornea,”Am. J. Ophthalmol. 96: 710-715 1983). The depth of incision with short intense pulses permitted great precision to be achieved in tests on freshly enucleated cow eyes. The photochemical laser-tissue interaction is not thermal, permitting direct breaks of organic molecular bonds without involving optical breakdown in adjacent tissue. Early experimental results in rabbits revealed problems of 1) corneal stromal swelling, probably in response to disturbed water relationships due to compromise of the epithelial barrier and severing of the lamellae and 2) rearrangement of endothelial cells resulting from loss of contact inhibition (Marshall, J. et al., “An ultrastructural study of corneal incisions induced by an excimer laser at 193 nm”, Ophthalmology 92: 749-758, 1985). Experiments with freshly enucleated human eyes indicated that flattening obtained by excimer laser ablation correlated with results of clinical scalpel radial keratotomy, but evaluation of the effects on wound healing and possible damage to adjacent structures was not addressed (Cotliar, A. M., et al., “Excimer laser radial keratotomy,” Ophthalmology 92: 206-208, 1985). It was, however, suggested that this laser may become very useful in applications including penetrating and lamellar keratoplasty, keratomileusis, and epikeratophakia. Control of the area and depth of pulses using photolithographed masks resulted in ability to produce narrow cuts (20 um) and at depths depending on pulse number (Puliafito, C. A., et al., “Excimer laser ablation of the cornea and lens”, 5 Ophthalmology 92: 741-748, 1985). These controlled ablations had only very narrow bands of destruction at the adjacent edges. These studies led to the quantitation of laser ablation (Kruegar, R. R. and S. L. Trokell “Quantitation of corneal ablation by ultraviolet laser light”, Arch. Ophthalmol. 103: 1741-1742, 1985). Excimer far UV radiation can be controlled to produce minimal adjacent tissue damage providing the angle and depth can be precisely controlled. The remaining problem of effects on healing could then be addressed.
- Wound healing was assessed in rabbits following excimer laser surface ablation (Hanna, K. D., et al., “Corneal stromal wound healing in rabbits after 193 run excimer laser surface ablation”,Arch. Ophthalmol. 107: 895-901, 1989). Healing appeared to be excellent except when over 85% to 90% of the corneal thickness had been cut. Endothelial cell disruption, junction separation and individual cell dropout occurred with corneal haze development with deeper cuts. A delivery system designed to deliver predictable depths of cut is, therefore, essential. Similar findings were reported in studies on human blind eyes (Taylor, D. M. et al., “Human excimer laser lamellar Keratectomy”, Ophthalmology 96: 654-664, 1989). Attention was directed to the challenges of improved procedures and equipment, the problems of individual variation, and the control of biologic responses to trauma before excimer laser lamellar keratectomy could become a clinically useful means of correcting refractive errors. In living monkey eyes, it was concluded that mild, typical wound healing occurred after excimer laser lamellar keratomileusis (Fantes, F. E., et al., “Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys”, Arch. Ophthalmol. 108: 665-675, 5 1990). All corneas were epithelialized by 7 days. By 6 weeks, mild to moderate haze was apparent with clearing by 6 to 9 months. The epithelium was thickened at 21 days after ablation, but returned to normal by 3 months. Subepithelial fibroblasts were three times the density of normal keratocytes, but returned to nearly normal numbers by 9 months. One conclusion reached was that control of the contour and uniformity of the ablated surface is important for the structural and biological responses of the cornea.
- Review of the literature clearly reveals that far UV vaporization (ablation with an excimer laser at 193 nm, for example) is a feasible means to sculpture or reprofile the cornea to correct nearsightedness, farsightedness, astigmatism, corneal scars, corneal densities, etc. The healing appears to parallel or to be equal to healing after scalpel intervention, providing the proper guidelines for pulsing and duration are followed. There remains a need to control the contour and uniformity of the ablated surface. Such control will reduce the adverse structural and biological response of the cornea and insure that a desired corrective change results.
- The use of a mask, of nearly identical optical density to the cornea, which can be preformed on the corneal surface so as to provide a smooth surface of exact contour and accurate dimensions would correct many of the problems that have prevented the precise control of the laser beam during keratotomy. This mask would be required to withstand exposure to moist gases direct tangentally to the corneal surface throughout the duration of exposure to the laser to remove ablated debris. The modulation of the beam energy distribution of the laser in a controlled fashion should also be provided by such a corneal mask. The use of a smooth ablatable mask having a known contour and having the density of the cornea would aid in insuring accurate direction and depth of a tangental cut utilizing a laser beam. The ablatable mask of the invention provides such advantages.
- Ionic polysaccharides have been used in the application of drugs by controlled release. Such ionic polysaccharides as chitosan or sodium alginate are disclosed as useful in providing spherical agglomerates of water-insoluble drugs in theJournal of Pharmaceutical Sciences, volume 78, number 11, November 1989, Bodmeier et al. Alginates have also been used as a depot substance in active immunization, as disclosed in the Journal of Pathology and Bacteriology, volume 77, (1959), C. R. Amies. Calcium alginate gel formulations have also found use as a matrix material for the controlled release of herbicides, as disclosed in the Journal of Controlled Release, 3 (1986) pages 229-233, Pfister et al. Alginates have also been used to form hydrogel foam wound dressings, as disclosed in U.S. Pat. No. 4,948,575.
- Compositions and a process for drug or diagnostic agent delivery by topical, injection, or body cavity delivery are disclosed. The pharmaceutical compositions in one embodiment of the invention contain pharmacologically active medicaments which are useful in providing treatments to ophthalmic areas of the mammalian body requiring the controlled release application of a medicament or requiring the administration of a diagnostic agent. In addition, the compositions of the invention are useful, with or without the inclusion of a medicament, as injectable compositions for depot drug delivery, as a protective corneal shield, as a second skin for application to wounds, as an ablatable corneal mask in a laser keratectomy process, or as medical devices, for instance, in the separation of organs, injured in surgical procedures or otherwise, in order to prevent the formation of undesirable adhesions as part of the healing process.
- The compositions of the invention provide a physiologically acceptable vehicle having a buffered pH and hypoosmotic, hyperosmotic, or isoosmotic characteristics. The pH and osmotic pressure is, preferably, made similar to bodily fluids, such as lacrimal tears. The pH and osmotic pressure of lacrimal tears is about pH 7.4 and 290 m0sm/kg. In addition, the pharmaceutical compositions are, optionally, sterilized so as to insure that the pharmaceutical compositions of the invention do not provide a source of infection.
- Polyphase systems are also useful and may contain non-aqueous solutes, non-aqueous solvents, and other non-aqueous additives. Homogeneous, polyphase systems can contain such additives as water insoluble high molecular weight fatty acids and alcohols, fixed oils, volatile oils and waxes, mono-, di-, and triglycerides, and synthetic, water insoluble polymers without altering the functionality of the system.
- The compositions of the invention in a preferred embodiment comprise aqueous mixtures of a film forming, water soluble polymer and an ionic polysaccharide, optionally containing a latent counter-ion to gel the polysaccharide upon release of the counter-ion. Alternatively, the compositions of the invention can comprise a two part aqueous system, one of which contains the ionic polysaccharide and film forming polymer and the other part containing an aqueous solution of a counter-ion.
- The counter-ion can be provided in latent form by microencapsulation in a heat sensitive medium, for instance, the walls of the microcapsule can be made of mono-, di-, or tri-glycerides or other natural or synthetic heat sensitive polymer medium. Alternatively, ion exchange resins can be incorporated in the compositions of the invention so as to release the desired counter-ion upon contact with an environment opposite in pH to the pH of the ion exchange resin. The aqueous mixture can be delivered to the ophthalmic area of the mammalian body requiring treatment as a low viscosity liquid at ambient temperatures. Activation of the latent form of the counter-ion gels the aqueous mixture in situ. The two part system can be separately applied to gel the mixture in situ. Because the compositions of the invention are low viscosity liquids at ambient temperatures, they easily pass to various ophthalmic areas insuring maximum contact between exposed tissue and the composition of the invention. The gel compositions of the invention can be either peeled away or allowed to be absorbed over time. The gels are gradually weakened upon exposure to mammalian body pH conditions.
- The useful film forming polymers are, preferably, water soluble polymers such as those which have been used in ophthalmic applications. The hydroxyalkyl cellulosics and methyl celluloses, sodium hyaluronate, and polyvinyl alcohol are representative polymers which have been found useful in ophthalmic applications.
- The useful ionic polysaccharides are natural polymers such as chitosan, gellan gum or alginates. Aqueous solutions of alginate ionic polysaccharides form gels upon contact with aqueous solutions of counter-ions such as calcium, strontium, aluminum, etc. Aqueous solutions of chitosan form gels upon contact with a metal tripolyphosphate counter-ion. The discovery forming the basis of this application is that when ionic polysaccharides are present in aqueous solutions in admixture with film forming polymers and a counter-ion, that such mixtures form useful gels. The osmolality of which can be calculated by assuming that the film forming polymer, if water soluble, does not contribute to the osmolality in the gel state.
- It has been found that aqueous pharmaceutical vehicles containing a film forming polymer and an ionic polysaccharide can be gelled and rendered resistant to shear thinning by contacting the mixture with a counter-ion. The gel compositions can be made isotonic or iso-osmotic and adjusted to the pH of mammalian body fluids, such as lacrimal tears. The pH and osmotic pressure of such bodily fluids are 7.4 and 29U mOsm/kg, respectively. It is advantageous to deliver a pharmacologically active medicament to an area of the mammalian body requiring pharmacological treatment under pH and osmotic pressure conditions which, for instance, match those of bodily fluids. Optionally, the, pharmaceutical compositions of the invention can be provided in a sterile condition.
- A complete listing of useful water soluble, film forming polymers is not possible. Representative useful polymers are the water soluble alkyl celluloses, i.e., methyl and ethyl cellulose; the hydroxyalkyl celluloses, i.e., hydroxypropylemethyl cellulose and hydroxyethyl cellulose; hyaluronic acid and water soluble salts thereof, i.e., sodium hyaluronate; chondroitin sulfate and water soluble salts thereof i.e., sodium chondroitin sulfate; polymers of acrylamide, acrylic acid, and polycyanoacrylates; polymers of methyl methacrylate and 2-hydroxyethyl methacrylate; polydextrose, cyclodextrin; polydextrin; maltodextrin, dextran; polydextrose; gelatin, collagen, natural gums, i.e. xanthan, locust bean, acacia, tragacanth, carrageenan, and agar; derivatives of polygalacturonic acid such as pectin; polyvinyl alcohol; polyvinyl pyrrolidone; polyethylene glycol; and polyethylene oxide. A preferred film forming agent is carboxymethyl ullulose and its sodium salt.
- More complete descriptions of some of the preferred water soluble, film forming polymers are as follows. Cyclodextrin also known as cycloamylose is a cyclic oligosaccharide. Cyclodextrins are produced by the enzyme conversion of prehydrolized starch to a mixture of alpha, beta, and gamma cyclodextrins and some linear dextrins. The cyclodextrins are composed of glucose units linked together by alpha (1-4) glycosidic bonds.
- Sodium hyaluronate also known as hyaluronic acid is composed of repeating units of sodium glucuronate and N-acetylglucosamine. Sodium hyaluronate was originally extracted from the comb of the rooster. Hyaluronic acid is a common biological agent present in a number of sources including the human umbilical cord. Sodium hyaluronate can also be manufactured by fermentation of a strain of streptococcus zooepidemicus.
- Polydextrose is a randomly bonded condensation polymer of dextrose which is only partially metabolized by mammals. The polymer can contain a minor amount of bound sorbitol, citric acid, and glucose.
- Chondroitin sulfate also known as sodium chondroitin sulfate is a mucopolysaccharide found in every part of human tissue, specifically cartilage, bones, tendons, ligaments, and vascular walls. This polysaccharide has been extracted and purified from the cartilage of sharks.
- Carrageenan is a linear polysaccharide having repeating galactose units and 3,6 anhydrogalactose units, both of which can be sulfated or nonsulfated, joined by alternating 1-3 and beta 1-4 glycosidic linkages. Carrageenan is a hydrocolloid which is heat extracted from several species of red seaweed and irish moss.
- Maltodextrins are water soluble glucose polymers which are formed by the reaction of starch with an acid and/or enzymes in the presence of water.
- Further details of the composition and derivation of other useful water soluble, film forming polymers can be found in the HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, published by the American Pharmaceutical Association Washington, D.C. copyright 1986, incorporated herein by reference.
- The gel forming ionic polysaccharides found useful in the represent invention are hydrophilic colloidal materials and include the natural gums such as gellan gum, alginate gums, i.e., the ammonium and alkali metal of salts of alginic acid and mixtures thereof. In addition, chitosan, which is the common name for deacetylated chitin is useful. Chitin is a natural product comprising poly-(N-acetyl-D-glucosamine). Gellan gum is produced from the fermentation of pseudomonas elodea to yield an extracellular heteropolysaccharide. The alginates and chitosan are available as dry powders from Protan, Inc., Commack, N.Y. Gellan gum is available from the Kelco Division of Merck & co., Inc. San Diego, Calif.
- Generally, the alginates can be any of the water-soluble alginates including the alkali metal alginates, such as sodium, potassium, lithium, rubidium and cesium salts of alginic acid, as well as the ammonium salt, and the soluble alginates of an organic base such as mono-, di-, or tri-ethanolamine alginates, aniline alginates, and the like. Generally, about 0.2% to about 1% by weight and, preferably, about 0.5% to about 3.0% by weight of gellan, alginate or chitosan ionic polysaccharides, based upon the total weight of the composition, are used to obtain the gel compositions of the invention.
- In general, the drug delivery composition of the invention will contain about 0.01% to about 60% by weight of medicament or pharmaceutical, about 1% to about 50% by weight of the water soluble, film forming polymer, together with the above amounts of ionic polysaccharide and the balance of water. In special situations, these amounts of gel forming ionic polysaccharide and water soluble, film forming polymer may be varied to increase or decrease the gel properties.
- Many polysaccharides may be used with the present invention to enhance the physical properties of the gel. For example, carboxymethylcellulose may reduce the rate of erosion of the polymer when compared to the polymer without the carboxymethylcellulose. In this regard, the carboxymethylcellulose competes with the polymer for the association of the water molecule, therefore, enhancing the stability of the gel to remain intact when in an aqueous environment.
- When polysaccharides are utilized to enhance the physical properties of the gel, cross-linking of the polysaccharide is not necessary.
- Polysaccharides that have not been crosslinked, and can be used to enhance the physical properties of the gel, include hydroxyalkyl cellulose and methylcellulose. More specifically, the useful polysaccharides are natural cellulose, hyaluronic acid and water soluble salts thereof, i.e. sodium hyaluronate, chondroitin sulfate and water soluble salts thereof, i.e. sodium chondroitin sulfate; polydextrose, cyclodextrin, polydextrin, maltodextrin, dextran; polydextrose; gelatin, collagen, natural gums, i.e. xanthan, locust bean, acacia, tragacanth, carrageenan, and agar, and derivatives of polygalacturonic acid such as pectin. A preferred polysaccharide is carboxymethylcellulose.
- The drug delivery composition of the invention will contain about a 0.1% to about 25% by weight of the non-crosslinked polysaccharide to enhance the physical properties of the gel.
- If an irreversible gel is required or an elastic gel, that is, one that retains its shape, cross-linking is required. Cross-linking is the physical, co-valent or ionic bonding of two or more molecules of the same polymer.
- Any cross linking agent having more than one functional group wherein the function group is either chemical or ionic may be utilized to cross link the polysaccharides described above.
- As known in the art, cross linking can occur between molecules of similar polymers by physical reaction as long as appropriate functional groups are present on the polymers.
- Useful counter-ions for gelling the gellan gum or alginate ionic polysaccharides in combination with the film forming, water soluble polymer compositions of the invention are cationic gelling agents, preferably, comprising a divalent or trivalent cation. Useful divalent cations include the alkaline earth metals, preferably, selected from the group consisting of calcium and strontium. Useful trivalent cations include aluminum. The most preferred counter-ions for gelling gellan gum or alginate ionic polysaccharides are contained in ionic compounds selected from pharmaceutically-acceptable gluconates, flourides, citrates, phosphates, tartrates, sulfates, acetates, borates, chlorides, and the like having alkaline earth metal cations such as calcium and strontium. Especially preferred counter-ion containing inorganic salts for use as ionic polysaccharide gelling agents include such inorganic salts as the chloride salts, such as strontium chloride, calcium chloride, and mixtures thereof. Generally, a molar ratio of counter-ion to gellan, 5 chitosan or alginate of about 1:1 to about 10:1, preferably, about 2:1 to about 5:1, and, most preferably, about 3:1 to about 5:1 is used.
- While the counter-ion, such as calcium or other counter-ions may be obtained by contact of the compositions of the invention with bodily fluids, it is preferred that a counter-ion in latent form be used in combination with the gellan gum or alginate ionic polysaccharide and film forming, water soluble polymer compositions of the invention. Alternatively, a counter-ion can be combined with the ionic polysaccharide and water soluble, film forming polymer compositions of the invention utilizing a two part system in which the counter-ion is topically or otherwise applied to the compositions of the invention subsequent to their topical or other application.
- Incorporation of the counter-ion in a latent form together with the ionic polysaccharide and film forming, water soluble polymer compositions of the invention may be accomplished by either encapsulating an aqueous solution of one of the counter-ion gelling agents, previously described above or by the incorporation of the counter-ion gelling agent into a matrix which provides for the controlled, slow-release of gelatin-encapsulated controlled release compositions disclosed in U.S. Pat. No. 4,795,642, incorporated herein by reference, disclose the preparation of a gelatin shell encapsulating a controlled release formulation in which the gelatin composition includes calcium chloride as the gelling agent. Alternatively, the counter-ion can be incorporated as an aqueous solution of a cationic gelling agent encapsulated in a vesical composed, for instance, of alphatocopherol, as disclosed in U.S. Pat. No. 4,861,580, incorporated herein by reference.
- Generally, aqueous compositions comprising chitosan can be gelled with multivalent anion gelling agents, preferably, comprising a metal polyphosphate, such as an alkali metal or ammonium polyphosphates, pyrophosphates, or metaphosphates. Representative metaphosphate, pyrophosphate, and polyphosphate gelling agents include sodium and potassium, polyphosphates, sodium and potassium pyrophosphates, sodium and potassium metaphosphates, and sodium and ammonium (mono-, di-, tri-) phosphates.
- With specific reference to the use of the compositions of the invention as ophthalmic drug delivery compositions, laser ablatable shields, or corneal protective compositions, it is noted that, generally, for the avoidance of adverse physiological effects to the eye, it is desirable that the pH and osmolality of the pharmaceutical vehicle be matched to the pH and osmolality of the eye. In addition, it is noted that a large percentage of drugs administered to the eye are lost as a result of lacrimal drainage. This applies especially in situations in which a liquid composition containing a pharmacologically active medicament is applied to the cornea of the eye. Accordingly, in such cases, only a small fraction of the pharmaceutical composition administered to the eye remains in contact with the cornea for a few minutes and an even smaller fraction penetrates into the cornea. To overcome these disadvantages, it is known to use viscous solutions, gels, ointments, or solid eye implants containing pharmacologically active medicaments. While progress has been made in the delivery of drugs by the use of solid implants, many patients find it difficult to tolerate the introduction of the implants into the conjunctival areas.
- To solve this problem, drug delivery vehicles which are liquid at room temperature and assume a semi-solid form at human body temperature have been proposed, such as those described in U.S. Pat. No. 4,188,373, which disclose the use of PLURONIC® polyols. In U.S. Pat. No. 4,861,760 and U.S. Pat. No. 4,474,751, ophthalmic drug delivery systems are disclosed which show liquid-gel phase transitions. In the '751 Patent, polymers are disclosed which are tetra substituted derivatives of ethylenediamine, propylenediamine, butylenediamine, pentylenediamine, or hexylenediamine. These are described as block copolymers of poly(oxypropylene) and poly(oxyethylene) of various chain lengths. These polymers were utilized as aqueous drug delivery vehicles contain from 10% to 50% by weight of polymer based on the weight of the total drug delivery vehicle. In the '760 Patent, the liquid-gel phase transition compositions for ophthalmological use contain polymers which form gels at concentrations 10-100 fold lower than those used in systems such as the '751 Patent, involving thermogelation. Accordingly, the drug delivery vehicles for the '760 Patent are said to be very well tolerated by the eye. The polymers utilized in the drug delivery vehicles of the '760 patent are described as polysaccharides obtained by fermentation of a microorganism.
- The drug delivery vehicles and corneal protective shield compositions of the invention are an improvement over those compositions used in prior art methods of ophthalmological drug delivery in that the compositions can be not only optimized for physiological tolerance in the eye by formulating the vehicles useful as drug delivery compositions so as to have isoosmotic, hyperosmotic, and hypoosmotic characteristics in the gel state but are made more useful because of increased resistance to shear thinning, as the result of higher gel strength. These advantages are obtained by the incorporation of an ionic polysaccharide in admixture with a film forming, water soluble polymer. By matching the osmolality of the drug delivery compositions of the invention, for instance, to those of the lacrimal fluid of the eye, it is possible to eliminate burning or other discomfort upon application of the drug delivery vehicles of the invention to the eye. The gel compositions formed upon contact with a counter ion for the ionic polysaccharide allow retention of the gel at the desired locus for longer intervals thus increasing the efficiency of action of the delivered drug. Drugs or diagnostic agents which can be administered by means of the drug delivery vehicles according to the invention are, for example:
- Antibacterial substances such as beta-lactam antibiotics, such as cefoxitin, n-formamidoylthienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides;
- aminoglycoside antibiotics such as gentamycin, kanamycin, amikacin, sisomicin and tobramycin;
- nalidixic acid and its analogs such as norfloxacin and the antimicrobial combination fluoroalanine/pentizidone, nitrofurazones and analogs thereof;
- antihistaminics and decongestants such as pyrilamine, chlorpheniramine, tetrahydrazoline, antazoline and analogs thereof; mast-cell inhibitors of histamine release, such as cromolyn;
- anti-inflammatories such as cortisone, hydrocortisone, hydrocortisone acetate, betamethasone, dexamethasone, dexamethasone sodium phosphate, prednisone, methylprednisolone, medrysone, fluorometholone, prednisolone, prednisolone sodium phosphate, triamcinolone, indainethacin, sulindac, its salts and its corresponding sulfides, and analogs thereof;
- miotics and anticholinergics such as echothiophate, pilocarpine, physostigmine salicylate, diisopropylfluorophosphate, epinephrine, dipivaloylepinephrine, neostigmine echothiopate iodine, demecarim bromide, carbamoyl choline chloride, methacholine, bethanechol, and analogs thereof;
- mydriatics such as atrophine, homatropine, scopolamine, hydroxyamphetamine, ephedrine, cocaine, tropicamide, phenylephrine, cyclopentolate, oxyphenonium, eucatropine, and analogs thereof;
- Other drugs can be used in the treatment of conditions and lesions of the eyes such as:
- antiglaucama drugs, for example, timalol, and especially its maleic salt and R-timolol and a combination of timolol or R-timolol with pilocarpine, as well as many other adrenergic agonists and/or antagonists: epinephrine and an epinephrine complex, or prodrugs such as bitartrate, borate, hydrochloride and dipivefrine derivatives; carbonic anhydrase inhibitors such as acetazolamide, dichlorphenamide, 2-(p-hydroxyphenyl)-thiothiophenesulfonamide, 6-hydroxy-2-benzothiazolesulfonamide; and 6-pivaloyloxy-2-benzothiazolesulfonamide;
- anitparasitic compounds and/or anti-protozoal compounds such as ivermectin, pyrimethamine, trisulfapidimidine, clindamycin and corticosteroid preparations;
- compounds having antiviral activity such as acyclovir, 5-iodo-2′-deoxyuridine (IDU), adenosine arabinoside (Ara-A), trifluorothymidine, interferon, and interferon-inducing agents such as poly I:C;
- antifungal agents such as amphotericin B, nystatin, flucytosine, natamycin and miconazole;
- anesthetic agents such as etidocaine cocaine, benoxinate, dibucaine hydrochloride, dyclonine hydrochloride, naepaine, phenacaine hydrochloride, piperocaine, proparacaine hydrochloride, tetracaine hydrochloride, hexylcaine, bupivacaine, lidocaine, mepivacaine and prilocaine;
- ophthalmic diagnostic agents, such as:
- (a) those used to examine the retina such as sodium fluorescein;
- (b) those used examine the conjunctiva, cornea and lacrimal apparatus, such as fluorescein and rose bengal; and
- (c) those used to examine abnormal pupillary responses such as methacholine, cocaine, adrenaline, atropine, hydroxyamphetamine and pilocarpine;
- opthalmic agents used as adjuncts in surgery, such as alpha-chymotrypsin and hyaluronidase;
- chelating agents such as ethylenediaminetetraacetic acid (EDTA) and deferoxamine;
- immunosuppressants and anti-metabolites such as methotrexate, cyclophosphamide, 6-mercaptopurine and azathioprine and combinations of the compounds mentioned above, such as antibiotics/antiinflammatories combinations such as the combination of neomycin sulfate and dexamethasone sodium phosphate and combinations concomitantly used for treating glaucoma, for example, a combination of timolol maleate and aceclidine.
- In general the drug delivery composition of the present invention will contain from about 0.01% to about 60% by weight of the medicament or pharmaceutical, from about 1% to about 50% of the polymer, the above amounts of ionic polysaccharide, and the balance water. In special situations, however, the amounts may be varied to increase or decrease the dosage schedule.
- If desired, the ophthalmic drug delivery vehicle, laser ablatable corneal mask, and corneal protective compositions of the invention may also contain preservatives, cosolvents, suspending agents, viscosity enhancing agents, ionic-strength and osmolality adjustors and other excipients in addition to the medicament and buffering agents. Suitable water soluble preservatives which may be employed in the inventive drug delivery vehicle are sodium bisulfite, sodium thiosulfate, is ascorbate, benzalkonilirn chloride, chlorabutanol, thimerosal, phenylmercurioborate, parabens, enzylalcohol phenylethanol and others. These agents may be present, generally, in amounts of about 0.001% to about 5% by weight and, preferably, in the amount of about 0.01 to about 2% by weight.
- Suitable water soluble buffering agents are alkali or alkali earth carbonates, phosphates, bicarbonates, citrates, borates, acetates, succinates and the like, such as sodium phosphate, citrate, borate, acetate, bicarbonate, carbonate and tromethamine (TRIS). These agents are present in amounts sufficient to maintain the pH of the system at 7.4±0.2 and preferably, 7.4. As such the buffering agent can be as much as 5% on a weight basis of the total composition.
- Representative buffering agents or salts useful in maintaining the pH at about 7.4±0.2 are alkali or alkali earth carbonates, chlorides, sulfates, phosphates, bicarbonates, citrates, borates, acetates and succinates. Representative preservatives are sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzylalcohol and phenylethanol.
- The corneal mask compositions of the invention are an improvement over the prior art thermo-reversible gels containing a polyoxyalkylene polymer as the sole polymer, in that the compositions of the invention provide greater gel strength because they are more resistant to shear thinning and are characterized as thermally-irreversible. These advantages are obtained by the incorporation of an ionic polysaccharide in admixture with a water soluble, film forming polymer. They can be optimized for optimum physiological tolerance in the eye by formulating the compositions so as to have a neutral pH and isotonic characteristics. These former advantages are obtained by the incorporation of an ionic polysaccharide in a mixture with a water soluble, film forming polymer. By matching the osmolality and pH of the laser ablatable corneal mask compositions of the invention to those of the lacrimal fluid of the eye, it is possible to eliminate burning or other discomfort upon application of the corneal mask of the invention to the eye. The higher gel strength compositions upon contact with a counter-ion allow retention of the gel as an in situ formed corneal mask for long intervals.
- The preparation of the drug delivery compositions, corneal protective compositions, and ablative corneal shield compositions of the invention is described below. The Examples which follow were prepared, generally, in accordance with the following preparation procedure. A mixture of a water soluble, film forming polymer and ionic polysaccharide is stirred or shaken in admixture with the aqueous buffer solution to bring about a more rapid solution of the polymer. The pharmacologically active medicaments and various additives such as salts and preservatives can subsequently be added and dissolved. In some instances the pharmacologically active substance must be suspended since it is insoluble in water. The pH of 7.4±0.2 is obtained by of appropriate buffering agents.
- The following Examples illustrate the various aspects of the invention but are not intended to limit its scope. Where not otherwise specified throughout this specification and claims, temperatures are given in degrees centigrade and parts, percentages, and proportions are by weight.
- In this Example there is described a composition of the invention suitable for ophthalmic use as a laser ablatable corneal mask or protective corneal shield. This composition was characterized as iso-osmotic and neutral in pH. An aqueous solution was made by dissolving the hydroxypropyl methyl cellulose in aqueous buffer solution together with the sodium alginate. The hydroxypropyl methyl cellulose was characterized as grade F50LV Premium, obtained from The Dow Chemical Company. The sodium alginate, characterized as high viscosity grade HF 120 was obtained from Protan, Inc. The proportions of ingredients in percent by weight are as follows:
Hydroxypropyl methyl cellulose 2.0 Sodium Alginate, high viscosity 1.0 Glycerin 0.25 Boric acid-sodium borate buffer 96.75 - The boric acid-sodium borate buffer was prepared as follows: In a two liter volumetric flask, 24.7 grams of boric acid and 3.8 grams of sodium borate decahydrate were dissolved in two liters of purified water, Usp. The formulation of this Example had a measured pH of 7.2 and an osmolality of 277 MOSM/Kg. A small amount of the formulation was placed on a glass slide and evenly spread so as to create a thin film. The film was subsequently sprayed with an aqueous solution of calcium chloride having a concentration of 21 to about 5% by weight. The film was characterized as strong, transparent, and resembled a thin, soft hydrophilic corneal contact lens which would be useful as a protective corneal mask or as an ablatable mask useful in laser keratectomy.
- The product was further characterized by measuring the average penetration in millimeters determined using a Precision Penetrometer with a ¼ size (9.38 grams, ASTM D-1043) cone and plunger. The penetration of the aqueous solution of polymers prepared above was greater than 20 mm. Subsequent to treatment of this solution with a few drops of a 2%-5% by weight aqueous solution of calcium chloride, a gel was formed in which the penetration was reduced to 5 mm.
- In these Examples there are described compositions of the invention for ophthalmic use as a corneal protective mask or as a laser ablatable corneal mask. Utilizing the same procedure as described in Example 1, an aqueous composition containing sodium hyaluronate and sodium alginate was prepared in two separate compositions. Sodium hyaluronate is commercially available from Meiji Seika Inc. Example 2 was hypoosmotic having an osmotic pressure of 249 mOSM/Kg and Example 3 was hyperosmotic having an osmotic pressure of 319 mosm/Kg. Both compositions were characterized as neutral in pH. The formulations have the following proportions by weight:
Example 2 Example 3 Sodium hyaluronate 1.0 1.0 Sodium Alginate, high viscosity 1.0 1.0 Glycerin 96.0 0.5 Boric acid-sodium borate buffer 98.0 97.5 - These compositions were evaluated as described in Example 1 by spreading a small amount of the formulation a glass slide and subsequently spraying the coated slide with a 5% by weight aqueous solution of calcium chloride. Similar strong, transparent, soft films were obtained which would be useful as a protective corneal shield or as a laser ablatable corneal mask.
- Example 3 was further characterized by measuring the average penetration in millimeters determined using a Precision Penetrometer with a ¼ size (9-38 grams, ASTM D-1043) cone and plunger. The penetration of the aqueous solution of polymers prepared above was greater than 20 mm. Subsequent to treatment of this solution with a few drops of a 2%-5% by weight aqueous solution of calcium chloride, a gel was formed in which the penetration was reduced to 5.9 mm.
- In this Example there is described a composition of the invention for ophthalmic use as a protective corneal shield or a laser ablatable corneal mask. An aqueous mixture comprising polyvinyl pyrrolidone and sodium alginate, high viscosity was prepared as follows: The percentages below are by weight.
Polyvinyl pyrrolidone 0.8 Sodium Alginate, high viscosity 1.0 Glycerin 0.3 Boric acid-sodium borate buffer 97.9 - The composition was characterized as neutral in pH having a pH of 7.2. The composition was hypoosmotic having an osmolality of 270 mOsm/Kg.
- The product was further characterized by measuring the average penetration in millimeters determined using a Precision Penetrometer with a ¼ (9.38, ASTM D-1043) cone and plunger. The penetration of the aqueous solution of polymers prepared above was greater than 20 mm. Subsequent to treatment of this solution with a few drops of a 5% by weight aqueous solution of calcium chloride, a gel was formed in which the penetration was reduced to 4.1 mm.
- In this Example there is described a composition of the invention for ophthalmic use as a laser ablatable mask or as a protective corneal shield. In accordance with the procedure of Example 1, chondroitin sulfate and sodium alginate were prepared as an aqueous solution utilizing the percentages by weight indicated below.
Sodium Chondroitin sulfate 2.0 Sodium Alginate, high viscosity 1.0 Glycerin 0.3 Boric acid-sodium borate buffer 96.7 - The aqueous solution was characterized as neutral in pH having a pH of 7.0. The aqueous solution was hyperosmotic having a measured osmolality of 354 mOsm/Kg. The penetration utilizing a Precision Penetrometer with a ¼ size cone, as described above, was greater than 20 mm prior to treatment with a few drops of a 2%-5% aqueous solution of calcium chloride. Subsequent to treatment with the aqueous calcium chloride solution, a gel was formed in which the penetration was reduced to 5.1 mm.
- Ion exchange resin beads sold under the trade name Duolite were treated so as to incorporate calcium by first treating a 30 gram sample of the ion exchange resin with a solution of 0.1 molar hydrochloric acid so as to allow for the exchange of protons for sodium. After three washings with 0.1 molar hydrochloric acid, the beads were washed with water and then washed twice with a 2% aqueous solution of calcium chloride. Each of the washing steps took place over a period of 16 hours (overnight). The beads were thereafter filtered and washed with water utilizing coarse filter paper and a Buchner glass filter assembly. The beads were then left overnight in a desiccator to dry. The dried beads of ion exchange resin which were obtained are utilized in the amount of 2 grams to fill a first compartment (close to the needle of the syringe) of a glass syringe utilized to apply liquids and dry materials. The syringe is sold under the trademark Hypak. Into the second compartment of the syringe, there is placed successively the solutions of Examples 1-5. Pushing the plunger of the syringe forward results in mixing the solution of Examples 1-5 with the ion exchange beads. After 5 to 10 minutes subsequent to mixing, the mixture is expelled from the syringe. After an additional 15 minutes the expelled material forms (without drying) a strong, transparent gel on the substrate on which it is expelled.
- These examples describe the successive application of an aqueous solution of Examples 1 and 3-5 to the cornea of a rabbit eye and the conversion of the aqueous liquid to a gel by the application of a 10% calcium chloride solution having a pH of 6.9. The calcium chloride solution is applied to the concave surface of a contact lens prior to contacting the surface of the aqueous liquid coating applied upon the cornea of the rabbit eye. After applying the compositions of Examples 1 and 3-5 to the cornea of a rabbit while place under general anesthesia, a liquid coating is formed upon the cornea. Subsequently, a 10% aqueous solution of calcium chloride is applied to the concave surface of a hard contact lens and the contact lens is placed over the coating on the cornea of the rabbit eye. The time required for the formation of a gel is less than 5 minutes. Thereafter, the contact lens is removed to expose a perfectly smooth and optically clear gelled surface of the composition of Examples 1 and 3-5. Excimer laser keratectomy is thereafter performed utilizing an argon fluoride excimer laser (193 mm). Further details of the excimer laser keratectomey process can be found inArchives of Ophthalmology, Vol. 106, Feb., 1988, entitled “Excimer Laser Keratectomy with a Rotating-slit Delivery System,” Hanna et al, incorporated herein by reference.
- These Examples describe drug compositions of the invention suitable for ophthalmic use in comparison with Control Examples in in-vitro tests for drug release.
- EXAMPLE 16 CONTROL—Forming no part of this invention
Percentage by weight Timolol maleate 0.50 Poloxamer 407 16.00 Sodium phosphate, monobasic, monohydrate 0.15 Sodium phosphate, dibasic 0.63 Glycerin 0.75 Sterile water 81.97 - An eye drop or medicated contact lens composition was prepared using a suitable glass container in which the sodium phosphate salts and glycerin were dissolved in sterile water. The polymer was next mixed with the buffer solution at 65° C. for 1 hour, followed by a further 2-3 hours in cold conditions. To a fixed weight of the polymer solution was added and dissolved, an accurate amount to timolol maleate (Huhtamaki OY Pharmaceuticals, Turku, Finland) to make a 0.5% w/w concentration.
- EXAMPLE 17 CONTROL—Forming no part of this invention
Percentage by weight Timolol maleate 0.50 Poloxamer 17.00 Sodium alginate, high viscosity 1.50 Sodium borate, decahydrate 0.16 Glycerin 1.00 Sterile water 81.27 - A medicated contact lens was prepared using a suitable glass container in which the sodium borate, boric acid and glycerin were dissolved in sterile water. Sodium alginate was sprinkled in with stirring to form a uniform paste. The polymer was next mixed with this mixture at 65° C. for 1 hour, and for a further 2-3 hours under cold conditions. To a fixed weight of the polymer-alginate solution, was added and dissolved, and accurate amount of timolol maleate (Huhtamaki OY Pharmaceuticals, Turku, Finland) to make a 0.5% w/w concentration.
-
Percentage by weight Timolol maleate 0.50 Sodium hyaluronate 1.00 Sodium alginate, high viscosity 1.00 Sodium borate, decahydrate 0.19 Glycerin 0.50 Sterile water 95.60 - A medicated contact lens was prepared using a suitable glass container in which the sodium borate, boric acid and glycerin were dissolved to make a solution in sterile water. Sodium alginate and sodium hyaluronate were sprinkled into this solution with continuous stirring to form a uniform paste. To a fixed weight of the hyaluronate-alginate mixture, there was added and dissolved an amount of timolol maleate (Huhtamaki OY Pharmaceuticals, Turku, Finland) to make a 0.5% w/w concentration.
- An in-vitro evaluation of the contact lens of Examples 16-18 was carried out as follows: The medicated contact lens was prepared by accurately weighing a big drop of the formulation on a glass microscopic slide (2′×1″). Two drops of a 5% by weight calcium chloride counter-ion solution was next placed on the formula drop. After 1 minute, the excess calcium chloride was blotted away from the now formed corneal contact lens.
- The glass slide with contact lens in place was next placed at the bottom of the 1 liter dissolution vessel containing 500 ml of purified water, maintained at 37° C. The dissolution experiment was carried out as per method 2 (paddle) of the United States Pharmacopoeia XXII, page 1579, The United States Pharmacopoeial Convention, Mack Publishing Company, 1990. Paddle stirring rate was 50 revolutions per minute.
- At regular time intervals, aliquots were removed from the vessels for analysis by High Pressure Liquid Chromatography. Six vessels were used for each formulation (n=6).
TIMOLOL MXLEATE DELIVERY FROM CORNEAL LENSES n = 6 TIME CUMULATIVE % OF TIMOLOL RELEASED (SD) Example 16 Example 17 Example 18 0 0.0 0.0 0.0 10 min 100.0 — — 30 min 100.0 — — 60 min 100.0 — — 120 min — 80.3 (12.0) 77.9 (6.2) 240 min — 90.0 (3.8) 93.9 (2.2) 360 min — 90.1 (3.1) 94.9 (2.5) 480 min — 95.7 (3.3) 97.5 (2.9) - It was observed that the drug is released in-vitro, by diffusion and not by the erosion of the lens. Approximately 80% of timolol maleate is released in 1 hour and the remaining amount gradually diffuses out in 3 to 4 hours. The lenses remained intact 48 hours after the start of the experiment. On the other hand, when 0.9% sodium chloride was used in place of purified water as the dissolution medium, the drug was released by both erosion and diffusion, within the first hour. The lenses are first reduced in size and then dissolved away within 6 hours. This erosion is dependent on the replacement of calcium ions (in the lens) with sodium ions (from the dissolution medium). The break up in-vivo is expected to be slow and gradual and is dependent on the sodium concentration in the tear fluid.
- In the following examples there are described compositions having multiple uses. For instance, they may be used as vehicles for drug delivery by topical application or by injection or useful as a protective corneal shield or in a process for excimer laser keratectomy as a laser ablatable corneal mask.
- The procedure for preparation and the polymeric materials utilized in the composition are those described in Example 1. The TRIS-hydrochloride buffer utilized in this composition was prepared utilizing the ingredients and proportions by weight indicated below.
TRIS (trcanethamine, USP) 0.6058 Concentrated hydrochloric acid 0.4123 Purified water, USP 100 - The composition was found to have a pH of 7.4 and an osmolality in mOsm/kg of 83. The procedure for preparation of this buffer is as follows: The weighed amount of TRIS was placed in a 2-liter volumetric flask and about 1 liter of purified water was added to the flask. The concentrated hydrochloric acid was added and the solution was made up to volume by adding the remaining water in the formulation.
- The calcium based counter-ion solution utilized to gel the inventive drug delivery compositions of Examples 19-22 was prepared utilizing the following proportion of ingredients in proportions by weight.
Calcium chloride, dehydrate 1.2 Calcium gluconate, anhydrous 3.0 - The composition had a pH of 6.88 and an osmolality in mOsm/kg of 299. The calcium based counter-ion solution was prepared as follows: The Calcium gluconate and calcium chloride in the required amount were placed in a 200 ml volumetric flask. Approximately 100 ml of water were added to partially dissolve the salts. The solution was, thereafter, warmed to 80° C. to facilitate dissolution. The solution was cooled and the remaining water was added to make up to 200 ml volume.
- A composition containing both sodium alginate and sodium hyaluronate was prepared for use as a vehicle for drug delivery, a laser ablatable corneal mask, a protective corneal shield, or a composition for use in preventing post-surgical adhesions. The proportions by weight are as follows:
Sodium hyaluronate 0.5 Sodium alginate 1.0 Sodium chloride 0.54 TRIS-hydrochloride Buffer 97.96 - The composition was found to have a pH of 7.6 and an osmolality of 297 mosm/kg prior to treatment with calcium ions by the addition of the previously described calcium based counter-ion solution. After treatment with calcium ions the osmolality was 302 mosm/kg.
- The product was further characterized by measuring the average penetration in millimeters as determined using a precision penetrometer with a ¼ size (9.38 grams, ASTM D-1043) cone and plunger. The penetration in millimeters prior to treatment of the composition of Example 19 with calcium ions was greater than 20 mm. After treatment with calcium ions the penetration was 4.77 mm.
- composition containing polyvinyl pyrrolidone and sodium alginate was prepared which is useful for the same applications as that formulation described in Example 19. The proportions in percent by weight of the ingredients of the composition are as follows:
Polyvinyl pyrrolidone 0.8 Sodium alginate 1.0 Sodium chloride 0.62 TRIS-hydrochloride buffer 97.58 - The composition had a pH of 7.59 and as osmolality in mOsm/kg prior to treatment with calcium ions of 320 and after treatment with calcium ions of 289.
- The penetration utilizing a precision penetrometer as further described in Example 19 was greater than 20 prior to treatment of the composition with calcium ions and 6.57 after treatment with calcium ions.
- A composition useful for the same uses as stated in Example 19 containing a combination of sodium alginate and chondroitin sulfate was prepared.
- The proportions of ingredients in percent by weight are as follows:
Sodium Chondroitin sulfate 2.0 Sodium alginate 1.0 Sodium chloride 0.35 TRIS-hydrochloride buffer 96.65 - The composition had a pH of 7.9 and an osmolality expressed in mOsm/kg of 301 prior to treatment with calcium ions and 272 after treatment with calcium ions.
- The penetration utilizing a precision penetrometer as further described in Example 19 was found to be greater than 20 mm prior to treatment with calcium counter-ions and 4.57 upon treatment with calcium ions utilizing the calcium counter-ions solution prepared above.
- A composition useful for the same uses as stated in Example 19 containing a combination of hydroxypropyl methyl cellulose, and sodium alginate was prepared. The proportions of ingredients and their percent by weight are as follows:
Hydroxypropyl methyl cellulose 2.0 Sodium alginate 1.0 Sodium chloride 0.6 TRIS-hydrochloride buffer 96.7 - The composition had a pH of 7.59 and an osmolality expressed in mOsm/kg of 326 prior to treatment with calcium ions and 301 after treatment with calcium ions.
- While this invention has been described with reference to certain specific embodiments, it will be recognized by those skilled in the art that many variations are possible without departing from the scope and spirit of the invention, and it will be understood that it is intended to cover all changes and modifications of the invention, disclosed herein for the purposes of illustration, which do not constitute departures from the spirit and scope of the invention.
Claims (20)
1. A drug delivery composition capable of gelling in situ containing approximately 0.01% to about 60% by weight of medicament or pharmaceutical, approximately 1-50% of water soluble film forming polymer and an ionic polysaccharide capable of cross-linking.
2. The drug delivery composition of claim 2 wherein the drug delivery composition is an aqueous composition.
3. The drug delivery composition of claim 2 wherein the drug delivery composition is a gel selected from the group consisting of hyperosmotic gel, hypoosmotic gel and an isoosmotic gel.
4. The drug delivery composition of claim 2 wherein the film forming polymer is water soluble.
5. The drug delivery composition of claim 2 wherein the film forming polymer is selected from the group consisting of methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hyalauronic acid and salts thereof, sodium hyaluronate, chondroitin sulfate, polyacrylic acid, polyacrylamide, polycyanolacrylades, alkyl methacrylatepolymers, hydroxyalkyl methacrylate polymers, cyclodextrin, polydextrose, dextran, gelatin, polygalacturonic acid, poly vinyl alcohol, polyvinyl pyrollidone, polyalkylene glycols and polyethylene alcohol.
6. The drug delivery composition of claim 2 wherein the film forming polymer is selected from the group consisting of cyclodextrin, polydextrose, carrageenan and maltodextrins.
7. The drug delivery composition of claim 2 wherein the ionic poysaccharide is selected from the group consisting of natural gums such as gellan gum, alginate gums, ammonium and alkali metal salts of alginic acid, chitin and chitosan.
8. The drug delivery composition of claim 8 wherein the alginate gums are alkali metal alginates and the metal is selected from the group consisting of sodium, potassium, lithium, rubidium and cesium salts.
9. The drug delivery composition of claim 2 wherein the medicament is selected from the group consisting of antibacterials, antihistamines, decongestants, antiinflammatories, antiparisitics, miotics, anticholinergies, antivirals, local anesthetics, antifungals, immunosuppressants, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anyhydrase inhibitors, opthalmic diagnostic agents, opthalimic agents used as adjuvents in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants and diagnostics.
10. The drug delivery composition of claim 2 wherein the medicament is an antibacterial substance selected from the group consisting of beta-lactam antibiotics, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides, gentamycin, kanamycin, amikacin, sisomicin, tobramycin.
11. A drug delivery composition capable of gelling in situ upon release of a counter ion containing approximately 0.01% to about 60% by weight of medicament or pharmaceutical, approximately 1-50% of water soluble film forming polymer and an ionic polysaccharide capable of cross-linking.
12. The drug delivery composition of claim 12 wherein the counter ion is provided in latent form by microencapsulation of the counter ion in a heat sensitive medium which releases the counter ion at body temperature and causes the drug delivery composition to gel.
13. The drug delivery composition of claim 12 wherein the drug delivery composition further contains ion exchange resins which release the counter ion to gel the drug delivery composition in situ.
14. The drug delivery composition of claim 12 wherein the drug delivery composition contains anticancer agents.
15. The drug delivery composition of claim 12 wherein the ionic poysaccharide is selected from the group consisting of natural gums such as gellan gum, alginate polysaccharides, ammonium and alkali metal salts of alginic acid and chitin.
16. The drug delivery composition of claim 12 wherein the ionic polysaccharide is selected from the group consisting of gellan gum and alganite polysaccharides and the counter ions for gelling the ionic polysaccharide are selected from the group consisting of calcium, strontium, sodium, potassium, lithium, rubidium, cesium salts, strontium chloride and calcium chloride.
17. A drug delivery composition which gels in situ which may be delivered topically to body cavities or by injection comprising approximately 0.01% to about 60% by weight of medicament or pharmaceutical, approximately 1-50% of water soluble film forming polymer, and an ionic polysaccharide which cross-links only after the drug delivery composition is administered in situ.
18. The drug delivery composition of claim 18 wherein the medicament of pharmaceutical is selected from the group consisting of antibacterials, antihistamines, decongestants, antiunflammatories, antiparisitics, miotics, anticholinergies, antivirals, local anesthetics, antifungals, immunosuppressants, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anyhydrase inhibitors, opthalmic diagnostic agents, opthalimic agents used as adjuvents in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants and diagnostics.
19. The drug delivery composition of claim 18 wherein the ionic poysaccharide is selected from the group consisting of natural gums such as gellan gum, alginate polysaccharides, ammonium and alkali metal salts of alginic acid and chitin.
20. The drug delivery composition of claim 18 wherein the drug delivery composition of is water soluble.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/234,922 US20030143274A1 (en) | 1991-10-30 | 2002-09-04 | Medical uses of in situ formed gels |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/785,305 US5318780A (en) | 1991-10-30 | 1991-10-30 | Medical uses of in situ formed gels |
US08/174,101 US5587175A (en) | 1991-10-30 | 1993-12-28 | Medical uses of in situ formed gels |
US08/773,755 US5958443A (en) | 1991-10-30 | 1996-12-23 | Medical uses of in situ formed gels |
US09/330,618 US6136334A (en) | 1991-10-30 | 1999-06-11 | Medical uses of in situ formed gels |
US62822700A | 2000-07-28 | 2000-07-28 | |
US10/234,922 US20030143274A1 (en) | 1991-10-30 | 2002-09-04 | Medical uses of in situ formed gels |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US62822700A Continuation | 1991-10-30 | 2000-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030143274A1 true US20030143274A1 (en) | 2003-07-31 |
Family
ID=25135059
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/785,305 Expired - Fee Related US5318780A (en) | 1991-10-30 | 1991-10-30 | Medical uses of in situ formed gels |
US08/174,101 Expired - Fee Related US5587175A (en) | 1991-10-30 | 1993-12-28 | Medical uses of in situ formed gels |
US08/773,755 Expired - Fee Related US5958443A (en) | 1991-10-30 | 1996-12-23 | Medical uses of in situ formed gels |
US09/330,618 Expired - Fee Related US6136334A (en) | 1991-10-30 | 1999-06-11 | Medical uses of in situ formed gels |
US10/234,922 Abandoned US20030143274A1 (en) | 1991-10-30 | 2002-09-04 | Medical uses of in situ formed gels |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/785,305 Expired - Fee Related US5318780A (en) | 1991-10-30 | 1991-10-30 | Medical uses of in situ formed gels |
US08/174,101 Expired - Fee Related US5587175A (en) | 1991-10-30 | 1993-12-28 | Medical uses of in situ formed gels |
US08/773,755 Expired - Fee Related US5958443A (en) | 1991-10-30 | 1996-12-23 | Medical uses of in situ formed gels |
US09/330,618 Expired - Fee Related US6136334A (en) | 1991-10-30 | 1999-06-11 | Medical uses of in situ formed gels |
Country Status (1)
Country | Link |
---|---|
US (5) | US5318780A (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040156880A1 (en) * | 2002-11-13 | 2004-08-12 | Nathan Ravi | Reversible hydrogel systems and methods therefor |
US20040185021A1 (en) * | 1992-02-11 | 2004-09-23 | Bioform Inc. | Tissue augmentation material and method |
US20050143718A1 (en) * | 2004-12-02 | 2005-06-30 | Sie Ag Surgical Instrument Engineering | Method for surgical treatment of a patient's eye by means of a laser |
US20050169895A1 (en) * | 2003-12-23 | 2005-08-04 | Melvik Jan E. | Use of alginate matrices to control cell growth |
DE102004014633A1 (en) * | 2004-03-22 | 2005-10-13 | Aesculap Ag & Co. Kg | Composition for adhesion prophylaxis |
US20050255142A1 (en) * | 2004-05-12 | 2005-11-17 | Surmodics, Inc. | Coatings for medical articles including natural biodegradable polysaccharides |
WO2005056075A3 (en) * | 2003-12-09 | 2006-02-02 | Transpharma Medical Ltd | Transdermal system for sustained delivery of polypeptides |
US20060106117A1 (en) * | 2004-11-12 | 2006-05-18 | Kimberly-Clark Worldwide, Inc. | Compound and method for prevention and/or treatment of vaginal infections |
US20060173551A1 (en) * | 1992-02-11 | 2006-08-03 | Bioform Inc. | Tissue augmentation material and method |
WO2006086775A2 (en) * | 2005-02-11 | 2006-08-17 | Duke University | Methods and compositions for reducing systemic toxicity of vectors |
US20060223765A1 (en) * | 2005-03-30 | 2006-10-05 | Kimberly-Clark Worldwide, Inc. | Method for inhibiting and/or treating vaginal infection |
US20070004672A1 (en) * | 2005-07-01 | 2007-01-04 | Dharmendra Jani | Long lasting alginate dry eye, related methods of manufacture and methods of use |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070065481A1 (en) * | 2005-09-21 | 2007-03-22 | Chudzik Stephen J | Coatings including natural biodegradable polysaccharides and uses thereof |
US20070065484A1 (en) * | 2005-09-21 | 2007-03-22 | Chudzik Stephen J | In situ occlusion using natural biodegradable polysaccharides |
US20070269488A1 (en) * | 2002-11-13 | 2007-11-22 | Nathan Ravi | Hydrogel Nanocompsites for Ophthalmic Applications |
DE102006033168A1 (en) * | 2006-07-10 | 2008-01-17 | Gelita Ag | Use of gelatin and a crosslinking agent for the preparation of a crosslinking therapeutic composition |
KR100852889B1 (en) | 2006-11-07 | 2008-08-19 | 이석근 | Algin-Cellulose Hybrid and method of the same that |
US20080274166A1 (en) * | 2005-06-10 | 2008-11-06 | Transpharma Medical Ltd. | Patch for Transdermal Drug Delivery |
US20080280853A1 (en) * | 2007-05-07 | 2008-11-13 | Erning Xia | Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same |
US20080287927A1 (en) * | 2004-12-02 | 2008-11-20 | Sie Ag Surgical Instrument Engineering | Protective device for ophthalmic laser treatment |
WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
US20090030525A1 (en) * | 2000-11-15 | 2009-01-29 | Bio Syntech Canada, Inc. | Method for restoring a damaged or degenerated intervertebral disc |
US20090075383A1 (en) * | 2005-11-04 | 2009-03-19 | Bio Syntech Canada Inc. | Composition and method for efficient delivery of nucleic acids to cells using chitosan |
US20090221489A1 (en) * | 2005-12-23 | 2009-09-03 | Kjell Stenberg | Water-Soluable Films Comprising Low-Viscosity Alginates |
US7619008B2 (en) | 2004-11-12 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Xylitol for treatment of vaginal infections |
US20090312724A1 (en) * | 2007-06-28 | 2009-12-17 | Cydex Pharmaceuticals, Inc. | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions |
US20100021545A1 (en) * | 1999-12-09 | 2010-01-28 | Biosyntech Canada Inc. | Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof |
US20100028434A1 (en) * | 1999-11-15 | 2010-02-04 | Bio Syntech Canada, Inc. | Temperature controlled and pH dependent self gelling biopolymeric aqueous solution |
US20100029549A1 (en) * | 1999-12-09 | 2010-02-04 | Biosyntech Canada Inc. | Situ self-setting mineral-polymer hybrid materials, composition and use thereof |
US20100041788A1 (en) * | 2006-02-06 | 2010-02-18 | Bioform Medical, Inc. | Implantation Compositions for Use in Tissue Augmentation |
WO2010030725A1 (en) * | 2008-09-15 | 2010-03-18 | Bausch & Lomb Incorporated | Compositions comprising polymers having amino sugar units and methods of making and using same |
US7691986B2 (en) | 1998-05-13 | 2010-04-06 | Nanotherapeutics, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
US7786176B2 (en) | 2005-07-29 | 2010-08-31 | Kimberly-Clark Worldwide, Inc. | Vaginal treatment composition containing xylitol |
US20100293807A1 (en) * | 2007-10-29 | 2010-11-25 | Transpharma Medical, Ltd. | Vertical patch drying |
US20110086008A1 (en) * | 2000-06-29 | 2011-04-14 | Hoemann Caroline D | Composition and method for the repair and regeneration of cartilage and other tissues |
CN102631711A (en) * | 2012-05-16 | 2012-08-15 | 金陵科技学院 | Hydrogel corneal contact lenses drug carrier |
CN102949331A (en) * | 2011-08-19 | 2013-03-06 | 苏州太湖美药业有限公司 | Preparation method of tobramycin ophthalmic in-situ gel eye-drops |
US20150119357A1 (en) * | 2013-10-24 | 2015-04-30 | Medtronic Xomed, Inc. | Chitosan stenting paste |
US20150119358A1 (en) * | 2013-10-24 | 2015-04-30 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
JP2017119693A (en) * | 2015-12-28 | 2017-07-06 | ライオン株式会社 | Ophthalmic composition and method for producing the same |
WO2017151651A1 (en) * | 2016-02-29 | 2017-09-08 | Belmont University | Pharmaceutical in situ gelling compositions |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
CN109529116A (en) * | 2019-01-29 | 2019-03-29 | 中国海洋大学 | It is a kind of for treating the NS-GAM gene activity bracket and preparation method thereof of scald |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
CN109793918A (en) * | 2018-12-29 | 2019-05-24 | 中国人民解放军总医院 | It can promote the plant society dressing of extensive wound hair follicle regeneration |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
CN110272636A (en) * | 2019-04-19 | 2019-09-24 | 丝耐洁(福建)口腔健康科技有限公司 | A kind of antibacterial plastic and the technique using this plastics-production plastic products |
CN110787126A (en) * | 2018-08-03 | 2020-02-14 | 武汉武药科技有限公司 | Moxifloxacin hydrochloride ophthalmic gel and preparation method thereof |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (323)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5626863A (en) * | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
JP3011768B2 (en) * | 1992-02-28 | 2000-02-21 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Photopolymerizable biodegradable hydrophilic gels as tissue contacting materials and controlled release carriers |
MX9304638A (en) * | 1992-07-31 | 1994-05-31 | Neose Pharm Inc | COMPOSITION TO TREAT AND INHIBIT GASTRIC AND DUODENAL ULCERS. |
JPH0776527A (en) * | 1993-06-28 | 1995-03-20 | Hayashibara Biochem Lab Inc | Semi-solid preparation and production thereof |
DK0797988T3 (en) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
ATE198418T1 (en) * | 1993-10-04 | 2001-01-15 | Maurizio Dr Tonetti | PHARMACEUTICAL COMPOSITION FOR PROMOTING TISSUE HEALING AND REGENERATION AND PHARMACEUTICAL COMPOSITION |
US5420197A (en) * | 1994-01-13 | 1995-05-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
WO1995020969A1 (en) * | 1994-02-04 | 1995-08-10 | University Of Southern California | Method for preventing keratocyte loss |
CA2140053C (en) * | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
US5578661A (en) * | 1994-03-31 | 1996-11-26 | Nepera, Inc. | Gel forming system for use as wound dressings |
US5462728A (en) * | 1994-04-05 | 1995-10-31 | Blank; Izhak | Pharmaceutical compositions |
US5827835A (en) * | 1994-08-30 | 1998-10-27 | Alcon Laboratories, Inc. | Thermally-gelling emulsions |
DK0725628T3 (en) * | 1994-08-30 | 2001-12-27 | Alcon Lab Inc | Thermal gel-forming drug delivery vehicles containing cellulose ethers |
US6099876A (en) | 1994-10-11 | 2000-08-08 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Temperature-stable liquid cells |
US5516808A (en) * | 1994-10-27 | 1996-05-14 | Sawaya; Assad S. | Topical cellulose pharmaceutical formulation |
US5607686A (en) * | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US5536243A (en) * | 1994-12-13 | 1996-07-16 | Jeyendran; Rajasingam S. | Time-release insemination device |
JP3297969B2 (en) * | 1994-12-26 | 2002-07-02 | ライオン株式会社 | Eye drops |
US5518732A (en) * | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
US5939485A (en) * | 1995-06-19 | 1999-08-17 | Medlogic Global Corporation | Responsive polymer networks and methods of their use |
US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
HU213450B (en) * | 1995-04-26 | 1997-06-30 | Ladanyi Jozsef | Gel contains gelatin and process for producing it |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US5716631A (en) * | 1995-09-29 | 1998-02-10 | Rdn Therapeutics Inc. | Long acting narcotic analgesics and antagonists |
US6387407B1 (en) | 1995-09-29 | 2002-05-14 | L.A.M. Pharmaceutical Corporation | Topical drug preparations |
US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
WO1997017038A1 (en) * | 1995-11-09 | 1997-05-15 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
US5866120A (en) | 1995-11-22 | 1999-02-02 | Advanced Corneal Systems, Inc. | Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase |
US6610292B2 (en) * | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
US5919574A (en) * | 1995-12-29 | 1999-07-06 | The United States Of America, As Represented By The Secretary Of Agriculture | Biodegradable laminated films fabricated from pectin and chitosan |
ATE302599T1 (en) * | 1996-05-24 | 2005-09-15 | Angiotech Pharm Inc | PREPARATIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES OF THE BODY PASSAGES |
US5836970A (en) * | 1996-08-02 | 1998-11-17 | The Kendall Company | Hemostatic wound dressing |
US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
FR2754712B1 (en) * | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | OPHTHALMIC COMPOSITIONS |
US5888493A (en) * | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
DE69705746T2 (en) * | 1996-12-20 | 2001-10-31 | Alza Corp | INJECTABLE DEPOT GEL PREPARATION AND PRODUCTION METHOD |
GB9707934D0 (en) * | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
DK0970175T3 (en) | 1997-07-29 | 2002-11-04 | Alcon Lab Inc | Conditioning solutions for the care of hard contact lenses |
ATE250923T1 (en) | 1997-07-29 | 2003-10-15 | Alcon Lab Inc | EYE DRUGS CONTAINING GALACTOMANNAN POLYMERS AND BORATE |
CA2212300A1 (en) * | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
GB2328443B (en) | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
US6589558B1 (en) | 1997-09-09 | 2003-07-08 | Ioannis G. Pallikaris | Photoablatable lenticular modulator |
EP1035833B1 (en) | 1997-12-02 | 2005-08-31 | Archimedes Development Limited | Compositions for nasal administration |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
US20020025921A1 (en) * | 1999-07-26 | 2002-02-28 | Petito George D. | Composition and method for growing, protecting, and healing tissues and cells |
US6174524B1 (en) | 1999-03-26 | 2001-01-16 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
FR2777189B1 (en) | 1998-04-09 | 2001-04-06 | Chauvin Lab Sa | OPHTHALMIC COMPOSITION COMPRISING A BETA-BLOCKER |
US6027744A (en) * | 1998-04-24 | 2000-02-22 | University Of Massachusetts Medical Center | Guided development and support of hydrogel-cell compositions |
US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
DK1085920T3 (en) * | 1998-05-13 | 2002-04-15 | Ml Lab Plc | Dextrin-containing preparation for the prevention of surgical adhesions |
GB9810127D0 (en) | 1998-05-13 | 1998-07-08 | Ml Lab Plc | Prevention of surgical adhesions |
US20020022588A1 (en) * | 1998-06-23 | 2002-02-21 | James Wilkie | Methods and compositions for sealing tissue leaks |
US6623751B2 (en) * | 1998-07-30 | 2003-09-23 | L'oreal S.A. | Cosmetic, pharmaceutical, or dermatological patch |
US6368625B1 (en) | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6605294B2 (en) * | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
WO2000012144A1 (en) * | 1998-08-31 | 2000-03-09 | Coloplast A/S | A composition capable of absorbing fluid |
AU757896B2 (en) * | 1998-09-02 | 2003-03-13 | Allergan, Inc. | Preserved cyclodextrin-containing compositions |
WO2000033764A1 (en) | 1998-12-04 | 2000-06-15 | Pathak Chandrashekhar P | Biocompatible crosslinked polymers |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
US20020197300A1 (en) * | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
US6410045B1 (en) * | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
AU3373500A (en) * | 1999-02-23 | 2000-09-14 | Ioteck, Inc. | Surgical anesthesia delivery system |
US20070038231A1 (en) | 1999-05-28 | 2007-02-15 | Ferree Bret A | Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft |
US20060247665A1 (en) * | 1999-05-28 | 2006-11-02 | Ferree Bret A | Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft |
US7273497B2 (en) | 1999-05-28 | 2007-09-25 | Anova Corp. | Methods for treating a defect in the annulus fibrosis |
ATE341345T1 (en) | 1999-06-11 | 2006-10-15 | Cytyc Corp | LIQUID GEL FORMULATION FOR DETECTING MILK DUCTS IN THE BREAST PRIOR TO SURGICAL ABLATION OF THE BREAST TISSUE |
DE19935231A1 (en) * | 1999-07-28 | 2001-02-01 | Ulrich Zimmermann | Crosslinking of ionotropic gels |
US6719797B1 (en) | 1999-08-13 | 2004-04-13 | Bret A. Ferree | Nucleus augmentation with in situ formed hydrogels |
ES2282134T3 (en) | 1999-09-11 | 2007-10-16 | THE PROCTER & GAMBLE COMPANY | POLYOXIALQUYLENE COPOLYMERS CONTAINING FLUID LIQUID VEHICLES. |
MXPA02004349A (en) | 1999-11-01 | 2003-09-22 | Alcon Inc | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum. |
US7575921B2 (en) * | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
US7560275B2 (en) * | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
US20030077302A1 (en) * | 2000-01-20 | 2003-04-24 | Gudrun Claus-Herz | Diclofenamide suspension gel |
US8455464B2 (en) * | 2000-01-21 | 2013-06-04 | Innovata Limited | Dextrin containing compositions for prevention of adhesions |
EP1281722A4 (en) * | 2000-02-03 | 2005-06-08 | Denki Kagaku Kogyo Kk | Hyaluronic acid gel, process for producing the same, and medical material containing the same |
FR2804870B1 (en) * | 2000-02-16 | 2002-08-16 | Oreal | COMPOSITE STRUCTURE WITH ADHESIVE MATRIX CONTAINING ONE OR MORE ACTIVE INGREDIENTS |
FR2805720B1 (en) | 2000-03-03 | 2002-08-16 | Oreal | DEVICE INCLUDING AN APPLICATOR AND / OR A MAGNETIC SPINNER |
US20030211974A1 (en) * | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
US6387858B1 (en) | 2000-03-31 | 2002-05-14 | Steris Inc. | Safe transport gel for treating medical instruments |
US6497887B1 (en) * | 2000-04-13 | 2002-12-24 | Color Access, Inc. | Membrane delivery system |
GB0011053D0 (en) * | 2000-05-09 | 2000-06-28 | Hudson John O | Medical device and use thereof |
KR20010107067A (en) * | 2000-05-25 | 2001-12-07 | 김정식 | A conglutination inhibitor |
US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
GB0015682D0 (en) * | 2000-06-28 | 2000-08-16 | Bristol Myers Squibb Co | Sprayable wound care composition |
DE10032456A1 (en) | 2000-07-04 | 2002-01-31 | Lohmann Therapie Syst Lts | Rapidly disintegrating dosage form for the release of active substances in the mouth or in the body cavities |
EP1196062B1 (en) | 2000-07-12 | 2005-10-26 | L'oreal | Device for packaging and/or applying a product containing fibres comprising at least a magnetised or magnetizable element |
JP2004503601A (en) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | Use of COX-2 inhibitors in the treatment and prevention of ocular COX-2-mediated diseases |
PE20020146A1 (en) * | 2000-07-13 | 2002-03-31 | Upjohn Co | OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR |
PT1305033E (en) | 2000-07-28 | 2005-01-31 | Alcon Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING TOBRAMYCIN AND XANTAN GUM |
ES2396598T3 (en) * | 2000-08-25 | 2013-02-22 | Senju Pharmaceutical Co., Ltd. | Preparations in the form of aqueous suspensions |
US20030219461A1 (en) * | 2000-09-12 | 2003-11-27 | Britten Nancy J. | Parenteral combination therapy for infective conditions |
US20040151765A1 (en) * | 2001-09-18 | 2004-08-05 | Ritchie Branson W. | Methods and compositions for wound management |
US20020091074A1 (en) * | 2000-09-20 | 2002-07-11 | Wooley Richard E. | Medical compositions, dressings and methods for treating microbial infections of skin lesions |
US20070003508A1 (en) | 2005-07-01 | 2007-01-04 | Wooley Richard E | Methods and compositions for promoting wound healing |
US20040208842A1 (en) * | 2001-09-18 | 2004-10-21 | Ritchie Branson W. | Antimicrobial cleansing compositions and methods of use |
AR031135A1 (en) | 2000-10-10 | 2003-09-10 | Upjohn Co | TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS |
DE10050870A1 (en) * | 2000-10-11 | 2002-08-01 | Knoell Hans Forschung Ev | Biocompatible composite material for medical applications |
US20020151050A1 (en) * | 2000-10-30 | 2002-10-17 | Vacanti Charles A. | Isolation of spore-like cells from tissues exposed to extreme conditions |
DE60137960D1 (en) * | 2000-11-15 | 2009-04-23 | Mohan A Chandavarkar | PHARMACEUTICAL COMPOSITIONS WITH CORTICOSTEROIDES AND ANTI-INFECTIVES |
US6989373B2 (en) * | 2000-11-15 | 2006-01-24 | Bio Syntech Canada Inc. | Method for restoring a fat-pad |
MXPA03004546A (en) * | 2000-11-22 | 2003-09-10 | Rxkinetix Inc | Treatment of mucositis. |
AU2002230504A1 (en) * | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic irrigating solution adapted for use in lasik surgery |
AU2002232437A1 (en) * | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic lubricating solution adapted for use in lasik surgery |
FR2819814B1 (en) * | 2001-01-22 | 2004-10-29 | Tbf Lab | BIOCOMPATIBLE AND IMPLANTABLE GELABLE COMPOSITION |
US6565530B2 (en) | 2001-02-28 | 2003-05-20 | Scimed Life Systems, Inc. | Immobilizing objects in the body |
US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
FR2822711B1 (en) * | 2001-03-28 | 2003-06-13 | Oreal | TREATMENT DEVICE COMPRISING AN ENVELOPE DEFINING A CAVITY IN WHICH A PART OF THE BODY MAY BE ENGAGED |
US20020183279A1 (en) * | 2001-04-18 | 2002-12-05 | Koichiro Tanaka | Pharmaceutical composition containing viscoelastic substance and medication |
US20030138494A1 (en) * | 2001-05-15 | 2003-07-24 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
US20030013753A1 (en) * | 2001-06-05 | 2003-01-16 | Ronald Aung-Din | Transdermal migraine therapy |
FR2825246B1 (en) * | 2001-06-05 | 2004-06-04 | Oreal | PACKAGING AND/OR APPLICATION DEVICE COMPRISING FIBERS COMPRISING PARTICLES CAPABLE OF ABSORBING A LIQUID OR A COMPOUND IN SOLUTION IN THIS LIQUID OR OF DISSOLVING IN A LIQUID |
US20050064012A1 (en) * | 2001-07-17 | 2005-03-24 | Baylor College Of Medicine | Process for causing myopic shift in vision |
US20030018382A1 (en) * | 2001-07-17 | 2003-01-23 | Pflugfelder Stephen C. | Process for improving vision |
DE10136722A1 (en) * | 2001-07-27 | 2003-02-13 | Evotec Ag | Inhibiting adhesion of particles to surfaces, useful e.g. for preventing cell adhesion in microanalytical systems, comprises adding polyol to a working solution |
US20030220376A1 (en) * | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
JO3429B1 (en) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
US20030104386A1 (en) * | 2001-08-31 | 2003-06-05 | The Regents Of The University Of California | Methods for the specific detection of redox-active tags and the use thereof for capillary gel electrophoresis and DNA sequencing |
EP1300165A1 (en) * | 2001-10-05 | 2003-04-09 | Marian L. Larson | Drug delivery via conformal film |
US7138133B2 (en) | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US7709026B2 (en) * | 2001-10-29 | 2010-05-04 | Columbia Laboratories, Inc. | Low concentration of peroxide for treating or preventing vaginal infections |
KR20040058101A (en) | 2001-11-14 | 2004-07-03 | 알자 코포레이션 | Catheter injectable depot compositions and uses thereof |
US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
KR20020011955A (en) * | 2001-12-26 | 2002-02-09 | 김정식 | A conglutination inhibitor |
CA2477044A1 (en) * | 2002-02-22 | 2003-09-04 | Pharmacia Corporation | Ophthalmic formulation with gum system |
MXPA04008173A (en) * | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride. |
KR100906547B1 (en) * | 2002-03-12 | 2009-07-07 | 에띠빠흠 | Composition having gelling properties for the prolonged delivery of bioactive substances |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
US20030204180A1 (en) * | 2002-04-30 | 2003-10-30 | Kimberly-Clark Worldwide, Inc. | Temperature responsive delivery systems |
US7084157B2 (en) * | 2002-05-17 | 2006-08-01 | Rajeev Raut | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation |
JP2005533782A (en) * | 2002-06-17 | 2005-11-10 | アルザ コーポレイション | An osmotic delivery system having an engine with fast extruding force and zero order including an osmotic agent dispersed in a fluid vehicle |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US20040001878A1 (en) * | 2002-06-26 | 2004-01-01 | Deroyal Industries, Inc. | Infused wound care dressings |
CA2493083C (en) * | 2002-07-16 | 2012-11-06 | Bio Syntech Canada Inc. | Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
US20040162315A1 (en) * | 2002-07-23 | 2004-08-19 | Hellberg Mark R. | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma |
CA2866848C (en) | 2002-07-30 | 2017-01-03 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
MXPA05001242A (en) | 2002-07-31 | 2005-06-08 | Alza Corp | Injectable depot compositions and uses thereof. |
ES2321505T3 (en) | 2002-07-31 | 2009-06-08 | Alza Corporation | COMPOSITIONS OF MULTIMODAL POLYMER DEPOSIT INJECTABLE AND USE OF THE SAME. |
CA2498717A1 (en) * | 2002-09-13 | 2004-03-25 | Ocular Sciences, Inc. | Devices and methods for improving vision |
US7438722B1 (en) * | 2002-09-20 | 2008-10-21 | Advanced Cardiovascular Systems, Inc. | Method for treatment of restenosis |
US7374776B2 (en) * | 2002-09-30 | 2008-05-20 | Regen Biotech, Inc. | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20080153894A1 (en) * | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
JP5583310B2 (en) * | 2002-12-20 | 2014-09-03 | チャクシュ・リサーチ・インコーポレーテッド | Ophthalmic formulation for prevention and treatment of ocular symptoms |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
US20040151680A1 (en) * | 2003-02-05 | 2004-08-05 | Patil Anjali Abhimanyu | Cosmetic compositions containing phenyl silicones |
CA2484424A1 (en) * | 2003-02-18 | 2004-09-02 | George H. Scherr | Alginate foam compositions |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
JP2006525405A (en) * | 2003-05-05 | 2006-11-09 | ベン‐グリオン ユニバーシティ オブ ザ ネゲヴ リサーチ アンド デベロップメント オーソリティ | Injectable cross-linked polymer preparations and their use |
AU2005211584B2 (en) * | 2003-05-05 | 2009-01-08 | Ben Gurion University Of The Negev Research And Development Authority | Injectable Cross-Linked Polymeric Preparations and Uses Thereof |
US7262179B2 (en) * | 2003-05-28 | 2007-08-28 | Bristol-Myers Squibb Company | Wound care compositions |
US20050118261A1 (en) * | 2003-06-12 | 2005-06-02 | Oien Hal J. | Compositions and methods of administering doxepin to mucosal tissue |
CA2529528A1 (en) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
CN1220528C (en) * | 2003-08-19 | 2005-09-28 | 大连永兴医用材料有限公司 | Carboxymethyl chitosan / carboxymethyl cellulose operative antiblocking film and method for making the same |
WO2005018607A1 (en) * | 2003-08-20 | 2005-03-03 | Ajinomoto Co., Inc. | Medicinal preparation having improved dissolution properties |
US8073538B2 (en) | 2003-11-13 | 2011-12-06 | Cardio Polymers, Inc. | Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart |
US20050119704A1 (en) * | 2003-11-13 | 2005-06-02 | Peters Nicholas S. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US20050277698A1 (en) * | 2004-01-05 | 2005-12-15 | Hughes Patrick M | Memantine delivery to the back of the eye |
CA2551064A1 (en) * | 2004-01-09 | 2005-07-21 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation |
WO2005091967A2 (en) * | 2004-03-03 | 2005-10-06 | University Of Georgia Research Foundation, Inc. | Methods and compositions for ophthalmic treatment of fungal and bacterial infections |
US20050199703A1 (en) * | 2004-03-09 | 2005-09-15 | Friedman Lawrence J. | Method and system for a host based smart card |
US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
DE102004019241A1 (en) * | 2004-04-16 | 2005-11-03 | Cellmed Ag | Injectable cross-linked and uncrosslinked alginates and their use in medicine and aesthetic surgery |
CN1972643A (en) | 2004-05-20 | 2007-05-30 | 库柏维景公司 | Corneal onlays and wavefront aberration correction to enhance vision |
TWI263501B (en) * | 2004-06-29 | 2006-10-11 | Taiwan Textile Res Inst | Sponge wound dressing made from chitin and alginate and method for forming the same |
JP2008505978A (en) * | 2004-07-12 | 2008-02-28 | アラーガン、インコーポレイテッド | Ophthalmic composition and eye disease treatment method |
JP4771044B2 (en) * | 2004-09-15 | 2011-09-14 | 大正製薬株式会社 | Mucosal fluid |
US20060079558A1 (en) * | 2004-09-27 | 2006-04-13 | Bridge Pharma. Inc. | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics |
WO2006036936A2 (en) * | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
US7473738B2 (en) * | 2004-09-30 | 2009-01-06 | Johnson & Johnson Vision Care, Inc. | Lactam polymer derivatives |
JP4954076B2 (en) * | 2004-10-01 | 2012-06-13 | メニコン シンガポール ピーティーイー. リミテッド | Contact lens packaging container solution |
GB2409162B (en) * | 2004-10-06 | 2005-12-14 | Bhk Holding Ltd | Materials,methods,and apparatus for treating a body cavity |
AU2005295927B2 (en) * | 2004-10-12 | 2012-02-02 | Fmc Biopolymer As | Self-gelling alginate systems and uses thereof |
US8246949B2 (en) * | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
DE102004055729A1 (en) * | 2004-11-18 | 2006-05-24 | Cellmed Ag | Production of two or more layered microcapsules |
CA2596194A1 (en) * | 2004-11-24 | 2006-06-01 | Algorx Pharmaceuticals, Inc. | Capsaicinoid gel formulation and uses thereof |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US8388995B1 (en) | 2006-02-03 | 2013-03-05 | Auburn University | Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform |
US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
JP2008529606A (en) * | 2005-02-04 | 2008-08-07 | オーバーン ユニバーシティ | Contact drug delivery system |
US8349352B2 (en) * | 2005-02-04 | 2013-01-08 | Auburn University | Therapeutic contact lenses with anti-fungal delivery |
US7726809B2 (en) * | 2005-02-09 | 2010-06-01 | Safilens S.R.L. | Contact lens, method for producing same, and pack for storage and maintenance of a contact lens |
US20060222596A1 (en) | 2005-04-01 | 2006-10-05 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
CN101262887A (en) * | 2005-07-15 | 2008-09-10 | 视可舒研究公司 | Prevention and treatment of ophthalmic complications of diabetes |
JP2009510049A (en) * | 2005-09-30 | 2009-03-12 | ガルデルマ・ソシエテ・アノニム | Use of at least one compound of the avermectin family or milbemycin family in the treatment of ophthalmic conditions |
FR2891460B1 (en) | 2005-09-30 | 2010-07-30 | Galderma Sa | USE OF AT LEAST ONE COMPOUND OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF OPHTHALMIC DISEASES DUE TO DEMODEX FOLLICULORUM. |
US20070082029A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
WO2007049952A1 (en) * | 2005-10-28 | 2007-05-03 | Nature Products Holding B.V. | Polymeric compound, method of preparing a polymeric compound, use of a polymeric compound |
WO2007051311A1 (en) * | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
CA2635603C (en) * | 2005-11-30 | 2016-01-19 | Endo Pharmaceuticals Inc. | Treatment of xerostomia |
FR2895907B1 (en) * | 2006-01-06 | 2012-06-01 | Anteis Sa | VISCOELASTIC GEL FOR DERMATOLOGICAL USE |
CA2635374C (en) | 2006-01-11 | 2015-12-08 | Hyperbranch Medical Technology, Inc. | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices |
US8252333B2 (en) * | 2006-01-26 | 2012-08-28 | Jorge Cueto-Garcia | Biodegradable, non-toxic biological adhesive for use in abdominal surgery |
US20070191816A1 (en) * | 2006-02-13 | 2007-08-16 | Boston Scientific Scimed, Inc. | Radio frequency induced drug elution |
US8062282B2 (en) * | 2006-02-13 | 2011-11-22 | Fossa Medical, Inc. | Methods and apparatus for temporarily occluding body openings |
US20070238789A1 (en) * | 2006-03-31 | 2007-10-11 | Chin-Ming Chang | Prednisolone acetate compositions |
US7883520B2 (en) | 2006-04-10 | 2011-02-08 | Forsight Labs, Llc | Corneal epithelial pocket formation systems, components and methods |
ITPD20060202A1 (en) * | 2006-05-22 | 2007-11-23 | Univ Degli Studi Trieste | POLYMERIC MIXTURES OF ANIONIC AND CATIONIC POLYSACCHARIDES AND THEIR USE |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
US20080069801A1 (en) * | 2006-06-13 | 2008-03-20 | Lee Randall J | Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
US9232938B2 (en) | 2006-06-13 | 2016-01-12 | Anova Corp. | Method and apparatus for closing fissures in the annulus fibrosus |
US8764835B2 (en) * | 2006-06-13 | 2014-07-01 | Bret A. Ferree | Intervertebral disc treatment methods and apparatus |
US8821549B2 (en) | 2006-06-13 | 2014-09-02 | Anova Corporation | Methods and apparatus for anulus repair |
US8834496B2 (en) | 2006-06-13 | 2014-09-16 | Bret A. Ferree | Soft tissue repair methods and apparatus |
WO2008001872A1 (en) * | 2006-06-28 | 2008-01-03 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition containing alginic acid or salt thereof |
BRPI0714386A2 (en) * | 2006-07-14 | 2012-12-25 | Fmc Biopolymer As | hydrogel, bead, methods for producing a hydrogel or bead, for implanting an implantable medical bead or device and cells in a patient, for blocking blood vessels, and for forming a hydrogel, implantable medical device, drug release formulation, contrast or radioopaque material, and, embolic therapeutic composition |
CA2655809C (en) * | 2006-07-21 | 2013-10-01 | Bridge Pharma, Inc. | Dermal anesthetic compounds |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
US8071135B2 (en) * | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
US20080107713A1 (en) * | 2006-11-08 | 2008-05-08 | Orilla Werhner C | Contact lens as a sustained drug delivery implant |
WO2008060575A2 (en) | 2006-11-13 | 2008-05-22 | Auburn University | Drug delivery system and method |
US20080132991A1 (en) * | 2006-11-30 | 2008-06-05 | Leonard Pinchuk | Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom |
WO2008073295A2 (en) * | 2006-12-07 | 2008-06-19 | Surmodics, Inc. | Latent stabilization of bioactive agents releasable from implantable medical articles |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
CN201075472Y (en) * | 2007-05-28 | 2008-06-18 | 富士康(昆山)电脑接插件有限公司 | Electric Connector |
US20080317819A1 (en) * | 2007-06-21 | 2008-12-25 | Orilla Werhner C | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas |
US20090004244A1 (en) * | 2007-06-27 | 2009-01-01 | Orilla Werhner C | Iris design as a drug depot for zonal drug delivery by contact lens |
US20090004245A1 (en) * | 2007-06-28 | 2009-01-01 | Orilla Werhner C | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
KR20100063744A (en) * | 2007-08-28 | 2010-06-11 | 에프엠씨 코포레이션 | Delayed self-gelling alginate systems and uses thereof |
US20090088723A1 (en) * | 2007-09-28 | 2009-04-02 | Accessclosure, Inc. | Apparatus and methods for treating pseudoaneurysms |
US20090149746A1 (en) * | 2007-11-19 | 2009-06-11 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20090143752A1 (en) * | 2007-12-03 | 2009-06-04 | Higuchi John W | Passive intraocular drug delivery devices and associated methods |
US20090142292A1 (en) * | 2007-12-03 | 2009-06-04 | Blackwell Richard I | Method For The Mitigation of Symptoms of Dry Eye |
CN101903822B (en) * | 2007-12-17 | 2012-11-28 | 莫尔研究应用有限公司 | Hyper-osmotic eye contact lens |
EP2082755A1 (en) * | 2008-01-16 | 2009-07-29 | CellMed AG | Monolithic alginate implants networked in situ |
DE102008005172A1 (en) * | 2008-01-19 | 2009-07-23 | Mike Ehrlich | Composition, useful for producing an agent for intraoperative application in abdominal cavity to prevent postoperative adhesion, comprises two components of polysaccharide, hyaluronic acid and/or phospholipid, and an antiinflammatory agent |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
PT103970A (en) | 2008-02-15 | 2009-08-17 | Ass For The Advancement Of Tis | HYDROGES BASED ON GELANA GUM FOR USE IN REGENERATIVE MEDICINE AND ENGINEERING OF FABRICS, ITS SYSTEM AND PROCESSING DEVICES |
JP5653342B2 (en) * | 2008-04-24 | 2015-01-14 | メドトロニック,インコーポレイテッド | Cold ionizing radiation sterilization |
EP2310002B1 (en) * | 2008-04-24 | 2016-11-02 | Medtronic, Inc | Protective gel based on chitosan and oxidized polysaccharide |
JP5757861B2 (en) | 2008-04-24 | 2015-08-05 | メドトロニック,インコーポレイテッド | Chitosan-containing protective composition |
JP2011518837A (en) | 2008-04-24 | 2011-06-30 | メドトロニック,インコーポレイテッド | Rehydratable thiolated polysaccharide particles and sponges |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
EP2276439A4 (en) | 2008-05-12 | 2013-11-27 | Univ Utah Res Found | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US8300252B2 (en) * | 2008-06-18 | 2012-10-30 | Livescribe, Inc. | Managing objects with varying and repeated printed positioning information |
WO2010005507A1 (en) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
US8207264B2 (en) * | 2008-07-11 | 2012-06-26 | Tyco Healthcare Group Lp | Functionalized inclusion complexes as crosslinkers |
WO2010033765A1 (en) * | 2008-09-19 | 2010-03-25 | The Trustees Of The University Of Pennsylvania | Solder formulation and use in tissue welding |
WO2010068281A2 (en) * | 2008-12-11 | 2010-06-17 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
EP2396070A4 (en) | 2009-02-12 | 2012-09-19 | Incept Llc | Drug delivery through hydrogel plugs |
US10980818B2 (en) * | 2009-03-06 | 2021-04-20 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
US20100233266A1 (en) * | 2009-03-13 | 2010-09-16 | Cleek Robert L | Articles and methods of treating vascular conditions |
JP5936536B2 (en) | 2009-03-16 | 2016-06-22 | ユニバーシティー オブ メンフィス リサーチ ファウンデーション | Compositions and methods for delivering agents to wounds |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
BR112012011183A2 (en) | 2009-11-12 | 2015-09-15 | Vbi Technologies Llc | isolated spore-like cell subpopulation and method for isolating a spore-like cell subpopulation |
KR101163415B1 (en) | 2010-01-06 | 2012-07-12 | 한남대학교 산학협력단 | Tissue adhesion barrier and method for preparing of the same |
EP2552406B1 (en) | 2010-03-26 | 2018-01-24 | Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. | Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof |
US20160145567A1 (en) * | 2010-05-27 | 2016-05-26 | Corning Incorporated | Cell culture article and methods thereof |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
FR2968996B1 (en) * | 2010-12-17 | 2013-04-12 | Anteis Sa | AQUEOUS INJECTABLE STERILE FORMULATION USED IN OPHTHALMOLOGY |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
DE102011007528A1 (en) | 2011-04-15 | 2012-10-18 | Aesculap Aktiengesellschaft | Thixotropic composition, in particular for post-surgical adhesion prophylaxis |
CN104039307A (en) * | 2011-04-22 | 2014-09-10 | 爱尔康研究有限公司 | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
AR082266A1 (en) | 2011-05-13 | 2012-11-28 | Univ Nac Del Litoral | INJECTABLE CONTROLLED LIBERATION MICROPARTICLE |
RU2465872C1 (en) * | 2011-06-09 | 2012-11-10 | Федеральное государственное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации | Method of prevention and treatment of excessive scarring after anti-glaucoma operation |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
WO2013188534A1 (en) * | 2012-06-12 | 2013-12-19 | Rutgers, The State University Of New Jersey | Biomaterials for the prevention of post-operative adhesions |
AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
US9662400B2 (en) | 2013-03-14 | 2017-05-30 | The University Of Memphis Research Foundation | Methods for producing a biodegradable chitosan composition and uses thereof |
CN105250995B (en) * | 2013-09-25 | 2018-06-22 | 河南汇博医疗股份有限公司 | Hyperplastic scar repairs pad pasting and preparation method thereof |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
EP3091985A4 (en) | 2014-01-10 | 2017-11-29 | Manistee Partners LLC | Treatment of migraines |
US9012402B1 (en) | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
US20160051723A1 (en) * | 2014-08-21 | 2016-02-25 | Gregory J. Pomrink | Bioresorbable tissue repair composition |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
TWI809304B (en) | 2014-12-01 | 2023-07-21 | 奥默羅斯公司 | Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions |
WO2016123693A1 (en) | 2015-02-06 | 2016-08-11 | The University Of British Columbia | Engineered tissue substitute system |
US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
US20160256410A1 (en) | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
JP2018515529A (en) | 2015-05-12 | 2018-06-14 | インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc | Drug delivery from hydrogels |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
ITUB20155788A1 (en) * | 2015-11-20 | 2017-05-20 | Hs Hospital Service Spa | COMPOSITIONS AND DEVICES FOR THE TREATMENT OF CANCER BY THERMAL ABLATION |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
EP3452023A1 (en) | 2016-05-05 | 2019-03-13 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
EP3536352A4 (en) * | 2016-11-07 | 2019-12-04 | Osaka University | Keratoconjunctival cover sheet and method for producing keratoconjunctival cover sheet |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
CN106943340A (en) * | 2017-04-28 | 2017-07-14 | 北京茗泽中和药物研究有限公司 | A kind of lidocaine hydrochloride jelly |
US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
US20210220515A1 (en) * | 2018-05-25 | 2021-07-22 | Eyebright Medical Technology (Beijing) Co., Ltd. | Viscoelastic agent material |
CN115666621A (en) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | Sustained release drug delivery systems with reduced impurities and related methods |
KR20230034315A (en) * | 2020-06-24 | 2023-03-09 | 세노겐 게엠베하 | Systems, methods and apparatus for ocular laser treatment |
CN114224821A (en) * | 2022-01-26 | 2022-03-25 | 沈阳药科大学 | Coated contact lenses comprising osmotically-compressive mechanism-based enhanced posterior ocular drug delivery systems and methods of making same |
CN115300453B (en) * | 2022-08-05 | 2024-04-02 | 山东大学 | Ophthalmic thermosensitive gel containing chloramphenicol nanoparticles and preparation method thereof |
CN115813816A (en) * | 2022-09-16 | 2023-03-21 | 江苏集萃功能材料研究所有限公司 | Mild gel mask and application thereof |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3590125A (en) * | 1969-10-10 | 1971-06-29 | Wyandotte Chemicals Corp | Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes |
US3640741A (en) * | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
US3867521A (en) * | 1970-08-26 | 1975-02-18 | Scherer Corp R P | Method for absorption of drugs |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4474753A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4511563A (en) * | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
US4540407A (en) * | 1983-11-14 | 1985-09-10 | Dunn Robert N | Surgical gloves and surface treatment of surgical gloves for avoiding starch peritonitis and the like |
US4570626A (en) * | 1984-01-20 | 1986-02-18 | Norris John L | Corneal light shield |
US4609640A (en) * | 1981-11-17 | 1986-09-02 | Toyo Jozo Company, Ltd. | Preparation having excellent absorption property |
US4767619A (en) * | 1981-09-14 | 1988-08-30 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Burn wound dressing material |
US4795642A (en) * | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
US4856513A (en) * | 1987-03-09 | 1989-08-15 | Summit Technology, Inc. | Laser reprofiling systems and methods |
US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
US4861760A (en) * | 1985-10-03 | 1989-08-29 | Merck & Co., Inc. | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US4883660A (en) * | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US4895724A (en) * | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
US4911926A (en) * | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
US4913903A (en) * | 1987-02-04 | 1990-04-03 | Alza Corporation | Post-surgical applications for bioerodible polymers |
US4948575A (en) * | 1989-01-24 | 1990-08-14 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
US5068225A (en) * | 1987-05-04 | 1991-11-26 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
US5071644A (en) * | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
US5080893A (en) * | 1988-05-31 | 1992-01-14 | University Of Florida | Method for preventing surgical adhesions using a dilute solution of polymer |
US5214093A (en) * | 1989-12-05 | 1993-05-25 | Nell Edward R | Adhesive formulation for nonsurgical blepheroplasty |
US5219895A (en) * | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5240710A (en) * | 1988-02-26 | 1993-08-31 | Niels Bukh | Method of treating conditions of teeth and their supporting tissue with sucralfate |
US5279611A (en) * | 1992-03-13 | 1994-01-18 | Mcdonnell Peter J | Laser shaping of ocular surfaces using ablation mask formed in situ |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5369131A (en) * | 1991-04-24 | 1994-11-29 | Poli Industria Chimica S.P.A. | Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam |
US5484610A (en) * | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
US5847023A (en) * | 1990-10-26 | 1998-12-08 | Mdv Technologies, Inc. | Thermal irreversible gel corneal contact lens formed in situ |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475753A (en) * | 1981-10-20 | 1984-10-09 | D Ath Philip O | Safety door lock |
CA1224148A (en) * | 1983-05-16 | 1987-07-14 | John L. Haslam | Drug delivery system utilizing thermosetting gels |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4983585A (en) * | 1987-05-04 | 1991-01-08 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
CA2011423A1 (en) * | 1989-03-07 | 1990-09-07 | Peter M. Taylor | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
KR0151704B1 (en) * | 1989-11-27 | 1998-10-15 | 아만 히데아키 | Fat emulsion |
CA2040460C (en) * | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Drug delivery with thermoreversible gels |
IT1248014B (en) * | 1991-06-07 | 1995-01-05 | Inverni Della Beffa Spa | PROTRACTED OPHTHALMIC PREPARATIONS |
EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
IT1255460B (en) * | 1992-07-28 | 1995-11-02 | Poli Ind Chimica Spa | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF MICROEMULSIONS OR BIOADHESIVE LIPOSOMIAL DISPERSIONS FOR THE TRANSMUCOSAL ADMINISTRATION OF PEPTIDAL SUBSTANCES AND PHARMACOLOGICALLY ACTIVE PROTEINS |
WO1994014415A1 (en) * | 1992-12-24 | 1994-07-07 | Hemagen/Pfc | Fluorocarbon emulsions |
ATE189772T1 (en) * | 1993-04-16 | 2000-03-15 | Wakamoto Pharma Co Ltd | WATER-BASED MEDICAL COMPOSITION THAT GELS REVERSIBLY UNDER HEAT |
BR9407728A (en) * | 1993-10-01 | 1997-02-12 | Syntex Inc | Oral suspensions of high doses of microfenolate mofetil |
MX9603858A (en) * | 1994-03-04 | 1997-12-31 | Univ Washington | Block and graft copolymers and methods relating thereto. |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
-
1991
- 1991-10-30 US US07/785,305 patent/US5318780A/en not_active Expired - Fee Related
-
1993
- 1993-12-28 US US08/174,101 patent/US5587175A/en not_active Expired - Fee Related
-
1996
- 1996-12-23 US US08/773,755 patent/US5958443A/en not_active Expired - Fee Related
-
1999
- 1999-06-11 US US09/330,618 patent/US6136334A/en not_active Expired - Fee Related
-
2002
- 2002-09-04 US US10/234,922 patent/US20030143274A1/en not_active Abandoned
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3590125A (en) * | 1969-10-10 | 1971-06-29 | Wyandotte Chemicals Corp | Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes |
US3640741A (en) * | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
US3867521A (en) * | 1970-08-26 | 1975-02-18 | Scherer Corp R P | Method for absorption of drugs |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4767619A (en) * | 1981-09-14 | 1988-08-30 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Burn wound dressing material |
US4609640A (en) * | 1981-11-17 | 1986-09-02 | Toyo Jozo Company, Ltd. | Preparation having excellent absorption property |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4511563A (en) * | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
US4540407A (en) * | 1983-11-14 | 1985-09-10 | Dunn Robert N | Surgical gloves and surface treatment of surgical gloves for avoiding starch peritonitis and the like |
US4570626A (en) * | 1984-01-20 | 1986-02-18 | Norris John L | Corneal light shield |
US4895724A (en) * | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
US4861760A (en) * | 1985-10-03 | 1989-08-29 | Merck & Co., Inc. | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
US4795642A (en) * | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US4913903A (en) * | 1987-02-04 | 1990-04-03 | Alza Corporation | Post-surgical applications for bioerodible polymers |
US4856513A (en) * | 1987-03-09 | 1989-08-15 | Summit Technology, Inc. | Laser reprofiling systems and methods |
US5068225A (en) * | 1987-05-04 | 1991-11-26 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
US5240710A (en) * | 1988-02-26 | 1993-08-31 | Niels Bukh | Method of treating conditions of teeth and their supporting tissue with sucralfate |
US5080893A (en) * | 1988-05-31 | 1992-01-14 | University Of Florida | Method for preventing surgical adhesions using a dilute solution of polymer |
US4883660A (en) * | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US4911926A (en) * | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
US4948575A (en) * | 1989-01-24 | 1990-08-14 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
US5214093A (en) * | 1989-12-05 | 1993-05-25 | Nell Edward R | Adhesive formulation for nonsurgical blepheroplasty |
US5071644A (en) * | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
US5847023A (en) * | 1990-10-26 | 1998-12-08 | Mdv Technologies, Inc. | Thermal irreversible gel corneal contact lens formed in situ |
US5484610A (en) * | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
US5219895A (en) * | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5369131A (en) * | 1991-04-24 | 1994-11-29 | Poli Industria Chimica S.P.A. | Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5279611A (en) * | 1992-03-13 | 1994-01-18 | Mcdonnell Peter J | Laser shaping of ocular surfaces using ablation mask formed in situ |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100100179A1 (en) * | 1992-02-11 | 2010-04-22 | Bioform Medical, Inc. | Tissue Augmentation Material and Method |
US20040185021A1 (en) * | 1992-02-11 | 2004-09-23 | Bioform Inc. | Tissue augmentation material and method |
US20100240946A1 (en) * | 1992-02-11 | 2010-09-23 | Bioform Medical, Inc. | Tissue Augmentation Material And Method |
US20110125288A1 (en) * | 1992-02-11 | 2011-05-26 | Merz Aesthetics, Inc. | Tissue Augmentation Material And Method |
US7968110B2 (en) | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US8067027B2 (en) | 1992-02-11 | 2011-11-29 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US20060173551A1 (en) * | 1992-02-11 | 2006-08-03 | Bioform Inc. | Tissue augmentation material and method |
US7691986B2 (en) | 1998-05-13 | 2010-04-06 | Nanotherapeutics, Inc. | High molecular weight, low methoxyl pectins, and their production and uses |
US7705135B2 (en) | 1998-05-13 | 2010-04-27 | Nanotherapeutics, Inc. | Pharmaceutical compositions comprising aloe pectins, and methods for their production and use |
US8920842B2 (en) | 1999-11-15 | 2014-12-30 | Piramal Healthcare (Canada) Ltd. | Temperature controlled and pH dependent self gelling biopolymeric aqueous solution |
US20100028434A1 (en) * | 1999-11-15 | 2010-02-04 | Bio Syntech Canada, Inc. | Temperature controlled and pH dependent self gelling biopolymeric aqueous solution |
US20100029549A1 (en) * | 1999-12-09 | 2010-02-04 | Biosyntech Canada Inc. | Situ self-setting mineral-polymer hybrid materials, composition and use thereof |
US8389467B2 (en) | 1999-12-09 | 2013-03-05 | Piramal Healthcare (Canada) Ltd. | In situ self-setting mineral-polymer hybrid materials, composition and use thereof |
US20100021545A1 (en) * | 1999-12-09 | 2010-01-28 | Biosyntech Canada Inc. | Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof |
US8747899B2 (en) | 1999-12-09 | 2014-06-10 | Piramal Healthcare (Canada) Ltd. | Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof |
US20110086008A1 (en) * | 2000-06-29 | 2011-04-14 | Hoemann Caroline D | Composition and method for the repair and regeneration of cartilage and other tissues |
US8258117B2 (en) | 2000-06-29 | 2012-09-04 | Piramal Healthcare (Canada) Ltd | Composition and method for the repair and regeneration of cartilage and other tissues |
US20090030525A1 (en) * | 2000-11-15 | 2009-01-29 | Bio Syntech Canada, Inc. | Method for restoring a damaged or degenerated intervertebral disc |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US20070269488A1 (en) * | 2002-11-13 | 2007-11-22 | Nathan Ravi | Hydrogel Nanocompsites for Ophthalmic Applications |
US20040156880A1 (en) * | 2002-11-13 | 2004-08-12 | Nathan Ravi | Reversible hydrogel systems and methods therefor |
US8192485B2 (en) * | 2002-11-13 | 2012-06-05 | The United States of America, as represented by the Department of Veterens Affairs | Reversible hydrogel systems and methods therefor |
WO2005056075A3 (en) * | 2003-12-09 | 2006-02-02 | Transpharma Medical Ltd | Transdermal system for sustained delivery of polypeptides |
US8541017B2 (en) | 2003-12-23 | 2013-09-24 | Fmc Biopolymer As | Use of alginate matrices to control cell growth |
US7790193B2 (en) | 2003-12-23 | 2010-09-07 | Fmc Biopolymer As | Use of alginate matrices to control cell growth |
US20100304484A1 (en) * | 2003-12-23 | 2010-12-02 | Fmc Biopolymer As | Use of Alginate Matrices to Control Cell Growth |
US20050169895A1 (en) * | 2003-12-23 | 2005-08-04 | Melvik Jan E. | Use of alginate matrices to control cell growth |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10799599B2 (en) | 2003-12-31 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10159752B2 (en) | 2003-12-31 | 2018-12-25 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10207008B2 (en) | 2003-12-31 | 2019-02-19 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
DE102004014633A1 (en) * | 2004-03-22 | 2005-10-13 | Aesculap Ag & Co. Kg | Composition for adhesion prophylaxis |
US20050255142A1 (en) * | 2004-05-12 | 2005-11-17 | Surmodics, Inc. | Coatings for medical articles including natural biodegradable polysaccharides |
US8241655B2 (en) * | 2004-05-12 | 2012-08-14 | Surmodics, Inc. | Coatings for medical articles including natural biodegradable polysaccharides |
US7619008B2 (en) | 2004-11-12 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Xylitol for treatment of vaginal infections |
US20060106117A1 (en) * | 2004-11-12 | 2006-05-18 | Kimberly-Clark Worldwide, Inc. | Compound and method for prevention and/or treatment of vaginal infections |
US20080287927A1 (en) * | 2004-12-02 | 2008-11-20 | Sie Ag Surgical Instrument Engineering | Protective device for ophthalmic laser treatment |
US20050143718A1 (en) * | 2004-12-02 | 2005-06-30 | Sie Ag Surgical Instrument Engineering | Method for surgical treatment of a patient's eye by means of a laser |
WO2006086775A2 (en) * | 2005-02-11 | 2006-08-17 | Duke University | Methods and compositions for reducing systemic toxicity of vectors |
US20110189262A1 (en) * | 2005-02-11 | 2011-08-04 | Duke University | Methods and Compositions for Reducing Systemic Toxicity of Vectors |
WO2006086775A3 (en) * | 2005-02-11 | 2007-02-08 | Univ Duke | Methods and compositions for reducing systemic toxicity of vectors |
US20060223765A1 (en) * | 2005-03-30 | 2006-10-05 | Kimberly-Clark Worldwide, Inc. | Method for inhibiting and/or treating vaginal infection |
US20080274166A1 (en) * | 2005-06-10 | 2008-11-06 | Transpharma Medical Ltd. | Patch for Transdermal Drug Delivery |
WO2007005421A2 (en) * | 2005-07-01 | 2007-01-11 | Bausch & Lomb Incorporated | Long lasting alginate dry eye, related methods of manufacture and methods of use |
US20070004672A1 (en) * | 2005-07-01 | 2007-01-04 | Dharmendra Jani | Long lasting alginate dry eye, related methods of manufacture and methods of use |
WO2007005421A3 (en) * | 2005-07-01 | 2007-06-07 | Bausch & Lomb | Long lasting alginate dry eye, related methods of manufacture and methods of use |
US7786176B2 (en) | 2005-07-29 | 2010-08-31 | Kimberly-Clark Worldwide, Inc. | Vaginal treatment composition containing xylitol |
US20070065481A1 (en) * | 2005-09-21 | 2007-03-22 | Chudzik Stephen J | Coatings including natural biodegradable polysaccharides and uses thereof |
US20070065484A1 (en) * | 2005-09-21 | 2007-03-22 | Chudzik Stephen J | In situ occlusion using natural biodegradable polysaccharides |
US8512736B2 (en) * | 2005-09-21 | 2013-08-20 | Surmodics, Inc. | Coatings including natural biodegradable polysaccharides and uses thereof |
US20090075383A1 (en) * | 2005-11-04 | 2009-03-19 | Bio Syntech Canada Inc. | Composition and method for efficient delivery of nucleic acids to cells using chitosan |
US20090221489A1 (en) * | 2005-12-23 | 2009-09-03 | Kjell Stenberg | Water-Soluable Films Comprising Low-Viscosity Alginates |
US8759282B2 (en) | 2005-12-23 | 2014-06-24 | Uppsalagruppen Medical Ab | Water-soluble films comprising low-viscosity alginates |
US9352046B2 (en) | 2006-02-06 | 2016-05-31 | Merz North America, Inc. | Implantation compositions for use in tissue augmentation |
US20100041788A1 (en) * | 2006-02-06 | 2010-02-18 | Bioform Medical, Inc. | Implantation Compositions for Use in Tissue Augmentation |
DE102006033168A1 (en) * | 2006-07-10 | 2008-01-17 | Gelita Ag | Use of gelatin and a crosslinking agent for the preparation of a crosslinking therapeutic composition |
KR100852889B1 (en) | 2006-11-07 | 2008-08-19 | 이석근 | Algin-Cellulose Hybrid and method of the same that |
US20080280853A1 (en) * | 2007-05-07 | 2008-11-13 | Erning Xia | Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same |
WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
WO2009006130A3 (en) * | 2007-06-28 | 2009-09-17 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
US20090312724A1 (en) * | 2007-06-28 | 2009-12-17 | Cydex Pharmaceuticals, Inc. | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions |
US20100293807A1 (en) * | 2007-10-29 | 2010-11-25 | Transpharma Medical, Ltd. | Vertical patch drying |
WO2010030725A1 (en) * | 2008-09-15 | 2010-03-18 | Bausch & Lomb Incorporated | Compositions comprising polymers having amino sugar units and methods of making and using same |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US11426306B2 (en) | 2009-05-18 | 2022-08-30 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
CN102949331A (en) * | 2011-08-19 | 2013-03-06 | 苏州太湖美药业有限公司 | Preparation method of tobramycin ophthalmic in-situ gel eye-drops |
CN102631711A (en) * | 2012-05-16 | 2012-08-15 | 金陵科技学院 | Hydrogel corneal contact lenses drug carrier |
US11253394B2 (en) | 2013-03-15 | 2022-02-22 | Dose Medical Corporation | Controlled drug delivery ocular implants and methods of using same |
US20150119357A1 (en) * | 2013-10-24 | 2015-04-30 | Medtronic Xomed, Inc. | Chitosan stenting paste |
US9192574B2 (en) * | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
AU2014340012B2 (en) * | 2013-10-24 | 2018-06-28 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
AU2014340006B2 (en) * | 2013-10-24 | 2018-06-28 | Medtronic Xomed, Inc. | Chitosan stenting paste |
US9192692B2 (en) * | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan stenting paste |
US20150119358A1 (en) * | 2013-10-24 | 2015-04-30 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
JP2017119693A (en) * | 2015-12-28 | 2017-07-06 | ライオン株式会社 | Ophthalmic composition and method for producing the same |
WO2017151651A1 (en) * | 2016-02-29 | 2017-09-08 | Belmont University | Pharmaceutical in situ gelling compositions |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
CN110787126A (en) * | 2018-08-03 | 2020-02-14 | 武汉武药科技有限公司 | Moxifloxacin hydrochloride ophthalmic gel and preparation method thereof |
CN109793918A (en) * | 2018-12-29 | 2019-05-24 | 中国人民解放军总医院 | It can promote the plant society dressing of extensive wound hair follicle regeneration |
CN109529116A (en) * | 2019-01-29 | 2019-03-29 | 中国海洋大学 | It is a kind of for treating the NS-GAM gene activity bracket and preparation method thereof of scald |
CN110272636A (en) * | 2019-04-19 | 2019-09-24 | 丝耐洁(福建)口腔健康科技有限公司 | A kind of antibacterial plastic and the technique using this plastics-production plastic products |
Also Published As
Publication number | Publication date |
---|---|
US6136334A (en) | 2000-10-24 |
US5958443A (en) | 1999-09-28 |
US5318780A (en) | 1994-06-07 |
US5587175A (en) | 1996-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6136334A (en) | Medical uses of in situ formed gels | |
US5077033A (en) | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide | |
EP0809486B1 (en) | Bio-erodible ophthalmic shield | |
CA1280367C (en) | Pharmaceutical composition of the type which undergoes liquid-gel phase transition | |
US5376693A (en) | Thermo-irreversible gel corneal contact lens formed in situ | |
US5300295A (en) | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH | |
US5403841A (en) | Use of carrageenans in topical ophthalmic compositions | |
US4983585A (en) | Viscoelastic fluid for use in surgery and other therapies and method of using same | |
US5071644A (en) | Topical drug delivery with thermo-irreversible gels | |
US4136177A (en) | Xanthan gum therapeutic compositions | |
US5880107A (en) | Sodium hyaluronate based ophthalmic formulation for use in eye surgery | |
US5847023A (en) | Thermal irreversible gel corneal contact lens formed in situ | |
CA1093466A (en) | Mixed xanthan gum and locust bean gum therapeutic compositions | |
EP0470703B1 (en) | Thermally reversible and irreversible gels | |
EP0126684B1 (en) | Drug delivery system utilizing thermosetting gels | |
CA2279982A1 (en) | Topical drug preparations | |
EP0029844B1 (en) | Method and composition for controlling corneal hydration | |
WO2011018800A2 (en) | A novel in-situ gel forming solution for ocular drug delivery | |
JPH11240838A (en) | Treatment of ophthalmic infection by azithromycin | |
EP1913948B1 (en) | Re-epithelializing pharmaceutical compositions containing xanthan gum | |
TW202228761A (en) | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine | |
US20040115271A1 (en) | Hydration compositions for corneal pre-surgery treatment | |
EP0359766A1 (en) | Improved viscoelastic fluid for ophthalmic surgery and method of using same | |
JPH0122248B2 (en) | ||
AU2003213858A1 (en) | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |